,Unnamed: 0,sha,drug,section,doi,title,year,sentence,posssible_hedge,corona_paper,corona_block,Is_Negated,Is_Negated_Orig,Unnamed: 13,annotation_expert_1,Treatment
0,0,0005d253951fedc237715a37db147032eea28912,lamivudine,body,10.1016/j.coviro.2014.08.002,Editorial overview: Antivirals and resistance: Advances and challenges ahead,2014.0,"Although currently available therapies include interferon variants, the approval of lamivudine in 1998 as the first nucleoside analogue effective on HBV infection was a significant advance",,True,True,0,0,0,0.0,therapies
1,1,0005d253951fedc237715a37db147032eea28912,ribavirin,body,10.1016/j.coviro.2014.08.002,Editorial overview: Antivirals and resistance: Advances and challenges ahead,2014.0,"Although a major antiviral agent in the treatment of HCV infection, ribavirin has been used to treat many other viral infections (most notably, viral hemorrhagic fevers) with multiple proposed effects on virus replication and propagation",,True,True,0,0,0,0.0,treat
2,2,0005d253951fedc237715a37db147032eea28912,ribavirin,body,10.1016/j.coviro.2014.08.002,Editorial overview: Antivirals and resistance: Advances and challenges ahead,2014.0,"For many years, the only approved therapies were combinations of interferon and ribavirin",,True,True,0,0,0,0.0,therapies
3,3,0005d253951fedc237715a37db147032eea28912,ribavirin,body,10.1016/j.coviro.2014.08.002,Editorial overview: Antivirals and resistance: Advances and challenges ahead,2014.0,"More recently (in December 2013), the HCV RNA polymerase inhibitor, sofosbuvir, received approval after showing that it could cure HCV infection in at least 90% of the treated patients, if properly combined with ribavirin or other more recently approved directly acting agents.",,True,True,0,0,0,0.0,cure
4,4,0005d253951fedc237715a37db147032eea28912,ribavirin,body,10.1016/j.coviro.2014.08.002,Editorial overview: Antivirals and resistance: Advances and challenges ahead,2014.0,"More recently (in December 2013), the HCV RNA polymerase inhibitor, sofosbuvir, received approval after showing that it could cure HCV infection in at least 90% of the treated patients, if properly combined with ribavirin or other more recently approved directly acting agents.",,True,True,0,0,0,0.0,cure
5,5,0005d253951fedc237715a37db147032eea28912,sofosbuvir,body,10.1016/j.coviro.2014.08.002,Editorial overview: Antivirals and resistance: Advances and challenges ahead,2014.0,"More recently (in December 2013), the HCV RNA polymerase inhibitor, sofosbuvir, received approval after showing that it could cure HCV infection in at least 90% of the treated patients, if properly combined with ribavirin or other more recently approved directly acting agents.",,True,True,0,0,0,0.0,cure
6,6,0005d253951fedc237715a37db147032eea28912,sofosbuvir,body,10.1016/j.coviro.2014.08.002,Editorial overview: Antivirals and resistance: Advances and challenges ahead,2014.0,"More recently (in December 2013), the HCV RNA polymerase inhibitor, sofosbuvir, received approval after showing that it could cure HCV infection in at least 90% of the treated patients, if properly combined with ribavirin or other more recently approved directly acting agents.",,True,True,0,0,0,0.0,cure
7,7,000affa746a03f1fe4e3b3ef1a62fdfa9b9ac52a,daptomycin,body,10.1016/j.jmii.2013.10.008,Correlation between antimicrobial consumption and incidence of health-care-associated infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 2000 to 2010,2015.0,"Tigecycline and daptomycin have been prescribed at the NTUH since 2007 and 2009, respectively",,False,False,0,0,0,0.0,prescribe
8,8,000affa746a03f1fe4e3b3ef1a62fdfa9b9ac52a,tigecycline,body,10.1016/j.jmii.2013.10.008,Correlation between antimicrobial consumption and incidence of health-care-associated infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 2000 to 2010,2015.0,"Tigecycline and daptomycin have been prescribed at the NTUH since 2007 and 2009, respectively",,False,False,0,0,0,0.0,prescribe
9,9,001916486b2012ccc611fe18d4763f9e81517cbb,pyrantel,body,10.1016/b978-012263951-7/50015-6,Chapter 12 Domestic Cats as Laboratory Animals,2002.0,Pyrantel pamoate (8-10 mg/kg PO q3 weeks x 3 treatments) is highly effective against both roundworms and hookworms and is cost-effective and easy to administer,may,True,False,0,0,0,0.0,effective
10,10,001916486b2012ccc611fe18d4763f9e81517cbb,progesterone,body,10.1016/b978-012263951-7/50015-6,Chapter 12 Domestic Cats as Laboratory Animals,2002.0,"Progesterone compounds and androgenic compounds can suppress estrus but are not recommended, because of the wide range of severe side effects associated with their use",may,True,False,1,1,0,1.0,suppress
13,13,0031e47b76374e05a18c266bd1a1140e5eacb54f,pfizerpen,body,10.1371/journal.pone.0230148,The fecal microbiota of healthy donor horses and geriatric recipients undergoing fecal microbial transplantation for the treatment of diarrhea,2020.0,"Horse W was ultimately diagnosed with enterolithiasis and Horse F was treated with broad-spectrum antimicrobials throughout the study period (Penicilin G Potassium 22,000 IU/kg intravenously every 6 hours, Pfizerpen, Pfizer, New York, NY; Enrofloxacin 7.5 mg/kg intravenously every 24 hours, Baytril 100, Bayer, Shawnee KS) beginning 4 hours prior to first sampling and FMT",,True,True,0,0,0,0.0,treated
14,14,00338998429de60726e4fe2dc07afaf65ed6f925,oxytetracycline,body,10.1016/s0737-0806(97)80046-9,Identification of an enzootic diarrhea (â€œShasta river crudâ€) in Northern California as potomac horse fever,1997.0,A blood sample for PCR was obtained prior to oxytetracycline therapy,may,False,False,0,0,0,0.0,therapy
15,15,0036b28fddf7e93da0970303672934ea2f9944e7,clotrimazole,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,A statistical analysis to predict persistence of canine sinonasal aspergillosis at endoscopic follow-up by comparing three different scoring systems: a retrospective study of 47 cases treated with one hour 1% clotrimazole per-endoscopic infusion and undergoing endoscopic follow-up The aim of this study was to investigate three different scoring system for Canine Sinonasal Aspergillosis (CSA) in order to predict whether they can indicate persistence of CSA at endoscopic follow-up.,,False,False,0,0,0,0.0,treated
16,16,0036b28fddf7e93da0970303672934ea2f9944e7,fipronil,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"Application of parasiticides was not always recorded; 6/29 dogs (21%) did not receive regular treatment, 7/29 were treated regularly with isoxazoline systemic products (24%), 2/29 with fipronil-based spot-ons (7%) and 2/29 (7%) with collars (one flumethrin-based and one unrecorded brand).",,False,False,1,1,0,0.0,treated
17,17,0036b28fddf7e93da0970303672934ea2f9944e7,trilostane,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"Comparison of different monitoring methods in dogs with hypercortisolism treated with trilostane Over the last years, many different studies investigated possible alternative methods with conflicting results",,False,False,0,0,0,0.0,treated
19,19,0036b28fddf7e93da0970303672934ea2f9944e7,itraconazole,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"Although itraconazole has previously been the drug of choice to treat DA, our findings show that combination therapy with terbinafine or newer anti-fungal treatment improves survival times",,False,False,0,0,0,0.0,treat
20,20,0036b28fddf7e93da0970303672934ea2f9944e7,itraconazole,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"Although itraconazole has previously been the drug of choice to treat DA, our findings show that combination therapy with terbinafine or newer anti-fungal treatment improves survival times",,False,False,0,0,0,0.0,treat
21,21,0036b28fddf7e93da0970303672934ea2f9944e7,terbinafine,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"Although itraconazole has previously been the drug of choice to treat DA, our findings show that combination therapy with terbinafine or newer anti-fungal treatment improves survival times",,False,False,0,0,0,0.0,therapy
22,22,0036b28fddf7e93da0970303672934ea2f9944e7,terbinafine,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"Although itraconazole has previously been the drug of choice to treat DA, our findings show that combination therapy with terbinafine or newer anti-fungal treatment improves survival times",,False,False,0,0,0,0.0,therapy
23,23,0036b28fddf7e93da0970303672934ea2f9944e7,chlorpheniramine,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"Premedication with intramuscular chlorpheniramine was administered, and 1-2 mL of sulfure hexafluoride microbubbles (SonoVueâ„¢) was injected around the tumour, followed by a local massage",,False,False,0,0,0,0.0,administered
24,24,0036b28fddf7e93da0970303672934ea2f9944e7,pimobendan,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"The following day, each cat received an echocardiography before (time 0), and 1, 3, and 6 hours after a single dose of 1.25 mg of pimobendan administered orally.",,False,False,0,0,0,0.0,administer
25,25,0036b28fddf7e93da0970303672934ea2f9944e7,clotrimazole,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,Sharp grade score can be used to predict treatment outcome in dogs treated with one hour 1% clotrimazole perendoscopic infusion,,False,False,0,0,0,0.0,treated
26,26,0036b28fddf7e93da0970303672934ea2f9944e7,trilostane,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,Hp seems to be the best parameter to monitor trilostane therapy.,,False,False,0,0,0,0.0,therapy
28,28,0036b28fddf7e93da0970303672934ea2f9944e7,exenatide,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,The objective of this study was to evaluate GV in cats receiving the GLP-1 analogue exenatide extended-release (EER) additionally to insulin therapy,,False,False,0,0,0,0.0,therapy
29,29,0036b28fddf7e93da0970303672934ea2f9944e7,glucagon,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"In humans with diabetes mellitus (DM), adding a glucagon-like peptide-1 (GLP-1) analogue to the conventional therapy results in significant reduction in GV",,False,False,0,0,0,0.0,therapy
30,31,0036b28fddf7e93da0970303672934ea2f9944e7,prednisolone,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"Twelve out of 14 cats (85.7%) developed GIH or GIDM within 3 months after the initiation of prednisolone therapy, the remaining two cats developed GIDM after 27 and 32 months",,False,False,0,0,0,1.0,therapy
31,32,0036b28fddf7e93da0970303672934ea2f9944e7,metronidazole,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"Metronidazole is frequently prescribed, however there is no evidence supporting its use, which could actually be associated with concerning gastrointestinal dysbiosis",,False,False,1,1,0,1.0,prescribe
32,33,0036b28fddf7e93da0970303672934ea2f9944e7,torasemide,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,The case records of cats treated with torasemide were reviewed,,False,False,0,0,0,0.0,treated
33,34,0036b28fddf7e93da0970303672934ea2f9944e7,itraconazole,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,The daily hazard of death from DA for dogs treated with itraconazole was 5.7 (95% CI 1.7 to 19) times that of dogs that were treated with other anti-fungal treatment,,False,False,0,0,0,1.0,treated
34,35,0036b28fddf7e93da0970303672934ea2f9944e7,terbinafine,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,The daily hazard of death from DA for dogs treated with terbinafine was 0.21 (95% CI 0.05 to 0.97) times that of dogs that were not treated with terbinafine.,,False,False,1,1,0,0.0,treated
35,36,0036b28fddf7e93da0970303672934ea2f9944e7,prednisolone,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"Patients were excluded if they received any other chemotherapeutic medication during this time, oral prednisolone therapy was permitted.",,False,False,1,1,0,0.0,therapy
36,37,0036b28fddf7e93da0970303672934ea2f9944e7,torasemide,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"This case series illustrates the therapeutic interest of torasemide in cats, which needs to be confirmed by further prospective clinical trials.",,False,False,0,0,0,0.0,therapeutic
37,38,0036b28fddf7e93da0970303672934ea2f9944e7,itraconazole,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,Twenty-four dogs (89%) were treated with itraconazole as first-line treatment (single agent in 12 dogs),,False,False,0,0,0,0.0,treated
38,39,0036b28fddf7e93da0970303672934ea2f9944e7,terbinafine,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,A total of nine dogs (33%) were treated concurrently with terbinafine,,False,False,0,0,0,0.0,treated
39,40,0036b28fddf7e93da0970303672934ea2f9944e7,prednisolone,body,10.1111/jvim.15658,Research Communications of the 29th ECVIMâ€CA Congress,2019.0,"In all the dogs treated only with Prednisolone, despite the clinical improvement, there were constant relapses",,False,False,0,0,0,0.0,treated
40,41,0036e8891c93ae63611bde179ada1e03e8577dea,ribavirin,body,10.1128/mbio.01065-19,Stable Occupancy of the Crimean-Congo Hemorrhagic Fever Virus-Encoded Deubiquitinase Blocks Viral Infection,2019.0,"Although ribavirin has been used to treat CCHF, its efficacy and utility in clinical settings remain under debate, and no licensed vaccines or alternative therapeutic options are available to prevent disease or treat patients",potential,True,False,1,1,0,0.0,treat
41,42,0036e8891c93ae63611bde179ada1e03e8577dea,ribavirin,body,10.1128/mbio.01065-19,Stable Occupancy of the Crimean-Congo Hemorrhagic Fever Virus-Encoded Deubiquitinase Blocks Viral Infection,2019.0,"Although ribavirin has been used to treat CCHF, its efficacy and utility in clinical settings remain under debate, and no licensed vaccines or alternative therapeutic options are available to prevent disease or treat patients",potential,True,False,1,1,0,0.0,treat
42,43,0036e8891c93ae63611bde179ada1e03e8577dea,ribavirin,body,10.1128/mbio.01065-19,Stable Occupancy of the Crimean-Congo Hemorrhagic Fever Virus-Encoded Deubiquitinase Blocks Viral Infection,2019.0,"Although ribavirin has been used to treat CCHF, its efficacy and utility in clinical settings remain under debate, and no licensed vaccines or alternative therapeutic options are available to prevent disease or treat patients",potential,True,False,1,1,0,0.0,treat
43,44,0043d044273b8eb1585d3a66061e9b4e03edc062,ethambutol,body,10.1186/1471-2458-12-1110,"Evaluation of the tuberculosis programme in Ningxia Hui Autonomous region, the Peopleâ€™s Republic of China: a retrospective case study",2012.0,"Following diagnosis, patients enter the DOTS program which prescribes short-course chemotherapy (SCC) comprising 2 months of isoniazid (H), rifampicin (R), pyrazinamide (Z) plus streptomycin (S) or ethambutol (E) followed by 4 months of H and R",,False,False,0,0,0,0.0,prescribes
44,45,0043d044273b8eb1585d3a66061e9b4e03edc062,isoniazid,body,10.1186/1471-2458-12-1110,"Evaluation of the tuberculosis programme in Ningxia Hui Autonomous region, the Peopleâ€™s Republic of China: a retrospective case study",2012.0,"Following diagnosis, patients enter the DOTS program which prescribes short-course chemotherapy (SCC) comprising 2 months of isoniazid (H), rifampicin (R), pyrazinamide (Z) plus streptomycin (S) or ethambutol (E) followed by 4 months of H and R",,False,False,0,0,0,0.0,prescribes
45,46,0043d044273b8eb1585d3a66061e9b4e03edc062,pyrazinamide,body,10.1186/1471-2458-12-1110,"Evaluation of the tuberculosis programme in Ningxia Hui Autonomous region, the Peopleâ€™s Republic of China: a retrospective case study",2012.0,"Following diagnosis, patients enter the DOTS program which prescribes short-course chemotherapy (SCC) comprising 2 months of isoniazid (H), rifampicin (R), pyrazinamide (Z) plus streptomycin (S) or ethambutol (E) followed by 4 months of H and R",,False,False,0,0,0,0.0,prescribes
46,47,0043d044273b8eb1585d3a66061e9b4e03edc062,rifampicin,body,10.1186/1471-2458-12-1110,"Evaluation of the tuberculosis programme in Ningxia Hui Autonomous region, the Peopleâ€™s Republic of China: a retrospective case study",2012.0,"Following diagnosis, patients enter the DOTS program which prescribes short-course chemotherapy (SCC) comprising 2 months of isoniazid (H), rifampicin (R), pyrazinamide (Z) plus streptomycin (S) or ethambutol (E) followed by 4 months of H and R",,False,False,0,0,0,0.0,prescribes
47,48,0043d044273b8eb1585d3a66061e9b4e03edc062,streptomycin,body,10.1186/1471-2458-12-1110,"Evaluation of the tuberculosis programme in Ningxia Hui Autonomous region, the Peopleâ€™s Republic of China: a retrospective case study",2012.0,"Following diagnosis, patients enter the DOTS program which prescribes short-course chemotherapy (SCC) comprising 2 months of isoniazid (H), rifampicin (R), pyrazinamide (Z) plus streptomycin (S) or ethambutol (E) followed by 4 months of H and R",,False,False,0,0,0,0.0,prescribes
49,50,007218eeeec5a82f0b40e97fb4133f29b03fc7bb,tamiflu,body,10.2217/fvl.09.53,Is systems biology the key to preventing the next pandemic?,2009.0,The effectiveness of targeted Tamiflu treatment and prophylactic measures in containing emerging influenza viruses is largely overestimated owing to differences in patient response to drug treatment and diminished drug efficacy against escape mutants that arise in response to therapy,,True,False,0,0,0,0.0,effectiveness
52,54,009fae49cceff4f95c97b252a02d4fb85fa05296,ampicillin,body,10.1016/b978-0-323-55512-8.00001-6,1 Tropical Lung Diseases,2020.0,Children aged 2-59 months with severe pneumonia should be treated with parenteral ampicillin (or penicillin) and gentamicin as a first-line treatment,,False,False,0,0,0,0.0,treated
53,55,009fae49cceff4f95c97b252a02d4fb85fa05296,gentamicin,body,10.1016/b978-0-323-55512-8.00001-6,1 Tropical Lung Diseases,2020.0,Children aged 2-59 months with severe pneumonia should be treated with parenteral ampicillin (or penicillin) and gentamicin as a first-line treatment,,False,False,0,0,0,0.0,treated
54,56,00a0ab182dc01b6c2e737dfae585f050dcf9a7a5,ribavirin,body,10.1016/j.virusres.2015.01.021,Middle East respiratory syndrome: An emerging coronavirus infection tracked by the crowd,2015.0,"Macaques were infected with 7 Ã— 10 6 TCID 50 of MERS-CoV and, 8 h after infection, they were treated with substantial amounts of subcutaneous IFN-â£2b along with intravenous ribavirin, followed by ribavirin doses intramuscularly every 8 h and with IFN-â£2b every 16 h until 72 h after infection ",,True,True,0,0,0,0.0,treated
57,59,00aa9cbf61505e3fa77ef009eafe04300a5c39b2,ribavirin,body,10.1016/s0140-6736(13)62707-5,Current status of rabies and prospects for elimination,2014.0,"94, 95 One individual who survived without post-exposure prophylaxis did so after the administration of an aggressive combination of medical treatments including the induction of a therapeutic coma, combined with ribavirin, ketamine, and amantadine treatment",,False,False,1,1,0,0.0,treatment
98,104,0110275ca0d02bc34fdda42fa1a9810dd11cd962,chloroquine,abstract,10.1016/j.drudis.2013.05.002,Chikungunya virus: an update on antiviral development and challenges,2013.0,Potential therapeutics that have been reported to show anti-CHIKV activity in vitro range from known broadspectrum antivirals like chloroquine to novel strategies involving RNA silencing technology,,True,False,0,0,0,0.0,therapeutic
118,126,0167dddb0e2783a60841b8e6f2b4e4cb981904e2,ampicillin,body,10.1292/jvms.14-0460,Three cases of idiopathic eosinophilic enteritis with chronic obstinate diarrhea in Japanese Black fattening cattle,2014.0,"In all cases, although therapeutic interventions consisting mainly of antibiotics, antidiarrheal drugs and vermicides administered when the diarrhea was observed had no therapeutic effect, the administration of dexamethasone (3âˆ’5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days) temporarily improved the fecal characteristics for a period of several days",,False,False,1,1,0,0.0,administered
119,127,0167dddb0e2783a60841b8e6f2b4e4cb981904e2,ampicillin,body,10.1292/jvms.14-0460,Three cases of idiopathic eosinophilic enteritis with chronic obstinate diarrhea in Japanese Black fattening cattle,2014.0,"In all cases, although therapeutic interventions consisting mainly of antibiotics, antidiarrheal drugs and vermicides administered when the diarrhea was observed had no therapeutic effect, the administration of dexamethasone (3âˆ’5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days) temporarily improved the fecal characteristics for a period of several days",,False,False,1,1,0,0.0,administered
120,128,0167dddb0e2783a60841b8e6f2b4e4cb981904e2,ampicillin,body,10.1292/jvms.14-0460,Three cases of idiopathic eosinophilic enteritis with chronic obstinate diarrhea in Japanese Black fattening cattle,2014.0,"In all cases, although therapeutic interventions consisting mainly of antibiotics, antidiarrheal drugs and vermicides administered when the diarrhea was observed had no therapeutic effect, the administration of dexamethasone (3âˆ’5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days) temporarily improved the fecal characteristics for a period of several days",,False,False,1,1,0,0.0,administered
121,129,0167dddb0e2783a60841b8e6f2b4e4cb981904e2,ampicillin,body,10.1292/jvms.14-0460,Three cases of idiopathic eosinophilic enteritis with chronic obstinate diarrhea in Japanese Black fattening cattle,2014.0,"In all cases, although therapeutic interventions consisting mainly of antibiotics, antidiarrheal drugs and vermicides administered when the diarrhea was observed had no therapeutic effect, the administration of dexamethasone (3âˆ’5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days) temporarily improved the fecal characteristics for a period of several days",,False,False,1,1,0,0.0,administered
122,130,0167dddb0e2783a60841b8e6f2b4e4cb981904e2,dexamethasone,body,10.1292/jvms.14-0460,Three cases of idiopathic eosinophilic enteritis with chronic obstinate diarrhea in Japanese Black fattening cattle,2014.0,"In all cases, although therapeutic interventions consisting mainly of antibiotics, antidiarrheal drugs and vermicides administered when the diarrhea was observed had no therapeutic effect, the administration of dexamethasone (3âˆ’5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days) temporarily improved the fecal characteristics for a period of several days",,False,False,1,1,0,0.0,administration
123,131,0167dddb0e2783a60841b8e6f2b4e4cb981904e2,dexamethasone,body,10.1292/jvms.14-0460,Three cases of idiopathic eosinophilic enteritis with chronic obstinate diarrhea in Japanese Black fattening cattle,2014.0,"In all cases, although therapeutic interventions consisting mainly of antibiotics, antidiarrheal drugs and vermicides administered when the diarrhea was observed had no therapeutic effect, the administration of dexamethasone (3âˆ’5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days) temporarily improved the fecal characteristics for a period of several days",,False,False,1,1,0,0.0,administration
124,132,0167dddb0e2783a60841b8e6f2b4e4cb981904e2,dexamethasone,body,10.1292/jvms.14-0460,Three cases of idiopathic eosinophilic enteritis with chronic obstinate diarrhea in Japanese Black fattening cattle,2014.0,"In all cases, although therapeutic interventions consisting mainly of antibiotics, antidiarrheal drugs and vermicides administered when the diarrhea was observed had no therapeutic effect, the administration of dexamethasone (3âˆ’5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days) temporarily improved the fecal characteristics for a period of several days",,False,False,1,1,0,0.0,administration
125,133,0167dddb0e2783a60841b8e6f2b4e4cb981904e2,dexamethasone,body,10.1292/jvms.14-0460,Three cases of idiopathic eosinophilic enteritis with chronic obstinate diarrhea in Japanese Black fattening cattle,2014.0,"In all cases, although therapeutic interventions consisting mainly of antibiotics, antidiarrheal drugs and vermicides administered when the diarrhea was observed had no therapeutic effect, the administration of dexamethasone (3âˆ’5 mg/head mixed with ampicillin and administered by intramuscular injection daily for 3 days) temporarily improved the fecal characteristics for a period of several days",,False,False,1,1,0,0.0,administration
266,288,02f57630fce1bd9a089b9f5b4689a4ef2a5810f3,acarbose,body,10.1016/b978-072160561-6.50021-6,Chapter 18 Ocular Manifestations of Systemic Diseases,2008.0,Acarbose may be used in diabetic animals whose glucose concentration is poorly controlled despite insulin therapy and dietary modification,may,True,True,0,0,0,0.0,therapy
324,350,0412cc57b0d374d1a4d059186745979429811050,progesterone,body,10.1016/s1473-3099(15)00524-1,Subacute sclerosing panencephalitis in pregnancy,2016.0,"Although many studies suggest systemic suppression of immunity takes place, which is mainly related to progesterone, this has not been proven",potential,False,False,1,1,0,1.0,supression
368,396,04c235b0224fdc67f03658734ae190aa76adcdde,acetate,body,10.1016/j.jfms.2010.01.014,Pituitary-dependent hyperadrenocorticism and generalised toxoplasmosis in a cat with neurological signs,2010.0,It is demonstrated that glucorticoids at clinical dosages (5 mg/kg body weight of methylprednisolone acetate administered intramuscularly weekly) for 4 weeks did not induce oocysts shedding in cats recently or chronically experimentally infected with T gondii,may,True,True,1,1,0,0.0,administer
451,489,05fef4a975bb02a917f4cef9ea57a3440769e9fb,acetate,body,10.1016/b978-1-4557-7397-8.00061-x,Chapter 61 Giraffidae,2015.0,"5 For contraception in females, melengestrol acetate (2-3 mg/kg/ day) administered in the feed, or the progesterone-derivative medroxyprogesterone acetate (Depo-Provera, Pfizer Animal Health), (450-800 mg/female, every 6 weeks) have been the traditional pharmaceutical means of contraception; however, the gonadotropinreleasing hormone (GnRH) agonist deslorelin (Suprelorin, Peptech Animal Health/Virbac) administered as implants has recently proven to be superior and effective for more than a year",,True,True,0,0,0,0.0,administered
546,608,07899a6af647ba443bf04599aa35d111d0d08cb3,acetate,body,10.3390/brainsci7070078,Multiple Sclerosis: Immunopathology and Treatment Update,2017.0,"Alternative treatment options involve disease-modifying therapies such as, interferons, glatiramer acetate, monoclonal antibodies and sphingosine-1-phosphate receptor modulators (Table 1, Figure 2 )",,False,False,0,0,0,0.0,therapies
547,609,07899a6af647ba443bf04599aa35d111d0d08cb3,glatiramer,body,10.3390/brainsci7070078,Multiple Sclerosis: Immunopathology and Treatment Update,2017.0,"Alternative treatment options involve disease-modifying therapies such as, interferons, glatiramer acetate, monoclonal antibodies and sphingosine-1-phosphate receptor modulators (Table 1, Figure 2 )",,False,False,0,0,0,0.0,therapies
548,610,07899a6af647ba443bf04599aa35d111d0d08cb3,acetate,abstract,10.3390/brainsci7070078,Multiple Sclerosis: Immunopathology and Treatment Update,2017.0,The most common injectable disease-modifying therapies in RRMS include Î²-interferons 1a or 1b and glatiramer acetate,,False,False,0,0,0,0.0,effectiveness
549,611,07899a6af647ba443bf04599aa35d111d0d08cb3,alemtuzumab,abstract,10.3390/brainsci7070078,Multiple Sclerosis: Immunopathology and Treatment Update,2017.0,"We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS.",,False,False,0,0,0,0.0,treatment
550,612,07899a6af647ba443bf04599aa35d111d0d08cb3,fingolimod,abstract,10.3390/brainsci7070078,Multiple Sclerosis: Immunopathology and Treatment Update,2017.0,"We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS.",,False,False,0,0,0,0.0,treatment
551,613,07899a6af647ba443bf04599aa35d111d0d08cb3,glatiramer,abstract,10.3390/brainsci7070078,Multiple Sclerosis: Immunopathology and Treatment Update,2017.0,The most common injectable disease-modifying therapies in RRMS include Î²-interferons 1a or 1b and glatiramer acetate,,False,False,0,0,0,0.0,therapies
552,614,07899a6af647ba443bf04599aa35d111d0d08cb3,mitoxantrone,abstract,10.3390/brainsci7070078,Multiple Sclerosis: Immunopathology and Treatment Update,2017.0,"We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS.",,False,False,0,0,0,0.0,treatment
553,615,07899a6af647ba443bf04599aa35d111d0d08cb3,ocrelizumab,abstract,10.3390/brainsci7070078,Multiple Sclerosis: Immunopathology and Treatment Update,2017.0,"We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS.",,False,False,0,0,0,0.0,treatment
554,616,07899a6af647ba443bf04599aa35d111d0d08cb3,ofatumumab,abstract,10.3390/brainsci7070078,Multiple Sclerosis: Immunopathology and Treatment Update,2017.0,"We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS.",,False,False,0,0,0,0.0,treatment
555,617,07899a6af647ba443bf04599aa35d111d0d08cb3,teriflunomide,abstract,10.3390/brainsci7070078,Multiple Sclerosis: Immunopathology and Treatment Update,2017.0,"We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS.",,False,False,0,0,0,0.0,treatment
587,650,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,acetate,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
588,651,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,acetate,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
589,652,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,acetate,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
590,653,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,glatiramer,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
591,654,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,glatiramer,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
592,655,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,glatiramer,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
593,656,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,mitoxantrone,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
594,657,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,mitoxantrone,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
595,658,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,mitoxantrone,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
596,659,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,natalizumab,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
597,660,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,natalizumab,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
598,661,07f3699e2eb7d0bfaad3848b07eb064f128df9dd,natalizumab,body,10.1016/j.pneurobio.2012.11.003,Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus,2013.0,"Successful therapies developed in the EAE model include glatiramer acetate (first line therapy), mitoxantrone and natalizumab (second line therapies: Kieseier and Hartung, 2003; Steinman and Zamvil, 2005) ",may,True,False,0,0,0,0.0,therapies
747,833,0b5fc9e7961738f048d064340557f653be8c7a86,acetaminophen,body,10.1016/b978-1-4160-2591-7.10126-2,Chapter 126 Hepatitis and Cholangiohepatitis,2009.0,S-Adenosylmethionine (SAMe) (20 mg/kg PO q24h) has been effective in treating acetaminophen toxicity,may,True,True,0,0,0,0.0,treating
817,908,0c5c7c0eda4954c87bac8bc496087b963d006796,acetate,body,10.1016/j.febslet.2014.09.024,Gut microbiome and the risk factors in central nervous system autoimmunity,2014.0,Peripheral blood mononuclear cells of patients with MS exacerbation have enhanced levels of Th17 cells (CCR6 + CD161 + ) when compared to patients treated with interferon (IFN)-b and glatiramer acetate [96] ,,True,True,0,0,0,0.0,treated
818,909,0c5c7c0eda4954c87bac8bc496087b963d006796,alemtuzumab,body,10.1016/j.febslet.2014.09.024,Gut microbiome and the risk factors in central nervous system autoimmunity,2014.0,"Approved MS therapeutics such as IFN-b and glatiramer acetate, and currently evaluated alemtuzumab potentiate the anti-inflammatory function of Treg cells in EAE and MS [98, 99] .",may,True,True,0,0,0,0.0,therapeutics
819,910,0c5c7c0eda4954c87bac8bc496087b963d006796,glatiramer,body,10.1016/j.febslet.2014.09.024,Gut microbiome and the risk factors in central nervous system autoimmunity,2014.0,Peripheral blood mononuclear cells of patients with MS exacerbation have enhanced levels of Th17 cells (CCR6 + CD161 + ) when compared to patients treated with interferon (IFN)-b and glatiramer acetate [96] ,,True,True,0,0,0,0.0,treated
947,1049,0e36dfaecf1ec02ad78ffe88d0fae80be2f0e17d,acetaminophen,body,10.1016/j.bjp.2018.07.009,"Toona sinensis: a comprehensive review on its traditional usages, phytochemisty, pharmacology and toxicology",2019.0,"sinensis attenuated acetaminophen-induced acute liver toxicity in HepG2 Cells and mice, and the related mechanisms is correlated to activating defensive genes and inhibiting pro-inflammatory mediators via suppressing JNK and p38 pathway.",could,True,False,0,0,0,1.0,suppress
987,1090,0ee107110147ceaedd656ae49069fbe7460d46a3,acetaminophen,body,10.1542/peds.2013-1501,Apnea in Children Hospitalized With Bronchiolitis,2013.0,"17 Exposure to various therapeutic agents (antibiotics, acetaminophen, and bronchodilators) during the week before admission appeared to have a ""protective"" association against apnea in unadjusted analyses",may,True,False,0,0,0,0.0,therapeutic
988,1091,0ee107110147ceaedd656ae49069fbe7460d46a3,acetaminophen,body,10.1542/peds.2013-1501,Apnea in Children Hospitalized With Bronchiolitis,2013.0,"Infants with apnea were significantly less likely to have been exposed to several therapeutic agents (antibiotics, acetaminophen, and bronchodilators) during the week before admission and were less likely to have attended day care (Table 1) ",,True,False,0,0,0,0.0,therapeutic
1005,1108,0f4ba828d02ce360d619447eca378043b3da2387,ceftiofur,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"Ceftiofur is also a good choice, and potentiated sulfonamides can be used for long-term therapy",,True,True,0,0,0,0.0,therapy
1006,1109,0f4ba828d02ce360d619447eca378043b3da2387,metronidazole,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"Foals with Tyzzer's disease may be treated with any of a number of antimicrobials as the agent appears very susceptible to penicillin, gentamicin, tetracycline, and metronidazole.",,True,True,0,0,0,0.0,treated
1007,1110,0f4ba828d02ce360d619447eca378043b3da2387,tetracycline,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"Foals with Tyzzer's disease may be treated with any of a number of antimicrobials as the agent appears very susceptible to penicillin, gentamicin, tetracycline, and metronidazole.",,True,True,0,0,0,0.0,treated
1008,1111,0f4ba828d02ce360d619447eca378043b3da2387,metronidazole,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"Neomycin (4 to 8 mg/kg PO, once) or metronidazole (low doses because of reduced hepatic metabolism (10 mg/kg PO q 12 h) may be administered to reduce enteric bacterial production of ammonia",,True,True,0,0,0,0.0,administered
1009,1112,0f4ba828d02ce360d619447eca378043b3da2387,neomycin,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"Neomycin (4 to 8 mg/kg PO, once) or metronidazole (low doses because of reduced hepatic metabolism (10 mg/kg PO q 12 h) may be administered to reduce enteric bacterial production of ammonia",,True,True,0,0,0,0.0,administered
1010,1113,0f4ba828d02ce360d619447eca378043b3da2387,cimetidine,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"For treating ulcers, famotidine or ranitidine should be utilized, because unlike cimetidine, they are excreted primarily in the kidneys and do not inhibit hepatic metabolism of other drugs.",,True,True,1,1,0,1.0,treat
1011,1114,0f4ba828d02ce360d619447eca378043b3da2387,famotidine,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"For treating ulcers, famotidine or ranitidine should be utilized, because unlike cimetidine, they are excreted primarily in the kidneys and do not inhibit hepatic metabolism of other drugs.",,True,True,1,1,0,0.0,treating
1012,1115,0f4ba828d02ce360d619447eca378043b3da2387,ranitidine,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"For treating ulcers, famotidine or ranitidine should be utilized, because unlike cimetidine, they are excreted primarily in the kidneys and do not inhibit hepatic metabolism of other drugs.",,True,True,1,1,0,0.0,treating
1013,1116,0f4ba828d02ce360d619447eca378043b3da2387,lactulose,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"Supportive care, lactulose, and a low-protein diet resulted in temporary clinical improvement in one of two foals that was treated, however the foal relapsed and was euthanized",,True,True,0,0,0,0.0,improvement
1014,1117,0f4ba828d02ce360d619447eca378043b3da2387,ivermectin,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"36, 37 Ivermectin is effective in treating Strongyloides westeri infestations",may,True,True,0,0,0,0.0,treating
1015,1118,0f4ba828d02ce360d619447eca378043b3da2387,metronidazole,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"Metronidazole, administered orally or intravenously (10 to 15 mg/kg, q 8 to 12 h), is indicated in clostridiosis cases",may,True,True,0,0,0,0.0,administer
1016,1119,0f4ba828d02ce360d619447eca378043b3da2387,dobutamine,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"If systemic blood pressure does not normalize in the face of a maximum or high CVP (>10 cm H 2 O), dobutamine should be administered as a Î²-agonist inotrope (2 to 20 Î¼g/kg/ minute)",,True,True,1,1,0,0.0,administered
1017,1120,0f4ba828d02ce360d619447eca378043b3da2387,amikacin,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"31 tiofur (10 mg/kg, IV, q 12 h) and amikacin (21 mg/kg, IV,  q 24 h) were administered to provide broad-spectrum antimicrobial coverage with potent Gram-negative efficacy",may,True,True,0,0,0,0.0,administered
1018,1121,0f4ba828d02ce360d619447eca378043b3da2387,flunixin,abstract,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"In addition, 50 mg of flunixin meglumine was given intravenously and a DSS and water enema was administered",,True,True,0,0,0,0.0,administered
1019,1122,0f4ba828d02ce360d619447eca378043b3da2387,meglumine,abstract,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"In addition, 50 mg of flunixin meglumine was given intravenously and a DSS and water enema was administered",,True,True,0,0,0,0.0,administered
1021,1124,0f4ba828d02ce360d619447eca378043b3da2387,acetylcysteine,body,10.1016/b978-1-4160-2353-1.50016-8,11 Gastrointestinal Disease,2006.0,"At the University of California, Davis, from 1987 to 2002, 41 out of 44 foals (93%) with meconium impactions were successfully treated medically with acetylcysteine enemas",,True,True,0,0,0,0.0,treated
1132,1246,103eac2f6aa6571542c28432251c609d2282a296,acetate,body,10.1016/b978-0-12-409527-4.00015-8,"Chapter 15 Biology and Diseases of Ruminants (Sheep, Goats, and Cattle)",2015.0,"Estrus may be suppressed in beef heifers in a feedlot setting by the feeding of melengestrol acetate, a synthetic progestogen.",,True,False,0,0,0,0.0,suppressed
1289,1423,11dc5e8970581b2744d9a935c0ce6eddded73073,acetate,body,10.1016/b978-1-4160-3969-3.00138-4,Rats,2013.0,ï‚™ Leuprolide acetate has been experimentally shown to suppress the ability of the pituitary-gonadal system to secrete gonadotropin and testosterone for over 5 weeks; similar to deslorelin because it may be useful in rats that cannot undergo ovariectomy â€¢ Melatonin induces apoptosis of rat prolactin-secreting tumors,may,True,False,1,1,0,0.0,suppress
1290,1424,11dc5e8970581b2744d9a935c0ce6eddded73073,leuprolide,body,10.1016/b978-1-4160-3969-3.00138-4,Rats,2013.0,ï‚™ Leuprolide acetate has been experimentally shown to suppress the ability of the pituitary-gonadal system to secrete gonadotropin and testosterone for over 5 weeks; similar to deslorelin because it may be useful in rats that cannot undergo ovariectomy â€¢ Melatonin induces apoptosis of rat prolactin-secreting tumors,may,True,False,1,1,0,0.0,suppress
1319,1455,120fdf24578441888a02e43eeee3e1a54661e3a3,acetate,body,10.1111/vaa.12207,Intravenous sufentanil-midazolam versus sevoflurane anaesthesia in medetomidine pre-medicated Himalayan rabbits undergoing ovariohysterectomy,2015.0,Intravenous Ringer acetate was administered at 20 mL kg Ã€1 hour Ã€1 during anaesthesia,,True,True,0,0,0,0.0,administer
1537,1693,13f7317a1b635f4b48d924ce11f0e4ef47bf19d6,abacavir,body,10.1016/s0378-6080(10)32029-0,29 Antiviral drugs,2010.0,"Warfarin has two enantiomers, R-warfarin and S-warfarin, which are substrates of CYP3A4 (R-warfarin), CYP1A2 (R-warfarin), and CYP2C9 (S-warfarin Gastrointestinal In patients with AIDSassociated dementia ADC taking optimal stable background antiretroviral therapy including either abacavir or placebo there was significantly more nausea in those who took abacavir (40 c ).",,False,False,0,0,0,0.0,therapy
1729,1906,16c8b4fe2b6ae40077de377027c4fdf6a27a0744,cyclophosphamide,body,10.4168/aair.2012.4.4.240,Two Series of Familial Cases With Unclassified Interstitial Pneumonia With Fibrosis,2012.0,"She was treated with steroids, cyclophosphamide, and hydroxychloroquine for 2 weeks",,True,False,0,0,0,0.0,treated
1730,1907,16c8b4fe2b6ae40077de377027c4fdf6a27a0744,hydroxychloroquine,body,10.4168/aair.2012.4.4.240,Two Series of Familial Cases With Unclassified Interstitial Pneumonia With Fibrosis,2012.0,"She was treated with steroids, cyclophosphamide, and hydroxychloroquine for 2 weeks",,True,False,0,0,0,0.0,treated
1865,2055,185e78aee848db9cc3a4510619048a6e4acd22cc,acetaminophen,body,10.1016/j.clml.2018.11.020,Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma,2019.0,Hydrocortisone was administered intravenously (50 mg) as well as oral acetaminophen and normal saline hydration,,True,True,0,0,0,0.0,administered
2481,2710,2008f024274c53b0de1276f4047a6a641813fd98,acetaminophen,body,10.1016/s1081-1206(10)61294-x,ABSTRACT BOOK,2005.0,"The remaining five successful patients had mild reactions which were treated symptomatically with acetaminophen, antihistamines or both",,False,False,0,0,0,0.0,treated
2613,2851,214c82a2c9adc01dcbf31a3977bc53698ac7f91b,acetaminophen,body,10.1016/b978-012373960-5.00568-2,Childhood Infectious Diseases: Overview,2008.0,"Mild or classic dengue is treated with antipyretic agents such as acetaminophen, bed rest, and fluid replacement (usually administered orally and only rarely parenterally)",,False,False,0,0,0,0.0,treated
2614,2852,214c82a2c9adc01dcbf31a3977bc53698ac7f91b,acetaminophen,body,10.1016/b978-012373960-5.00568-2,Childhood Infectious Diseases: Overview,2008.0,"Mild or classic dengue is treated with antipyretic agents such as acetaminophen, bed rest, and fluid replacement (usually administered orally and only rarely parenterally)",,False,False,0,0,0,0.0,treated
2792,3040,239da66e7f71763fd7180b5fb831de6202eb09db,acetate,body,10.1016/b978-1-4377-0651-2.10015-3,Chapter 15 Systemic or Multifocal Signs,2011.0,The anabolic steroid trenbolone acetate also is beneficial given in 30-mg doses administered intramuscularly (IM),,True,False,0,0,0,0.0,administer
2894,3153,24c20b8ab487acad45bb797b2ae0a2a910b31043,acetaminophen,body,10.1155/2012/236345,Eicosanoids and Respiratory Viral Infection: Coordinators of Inflammation and Potential Therapeutic Targets,2012.0,"Human volunteers challenged with RV showed increased nasal symptoms and a suppressed serum neutralizing antibody response when treated with aspirin or acetaminophen, suggesting a protective role for COX products in reducing symptoms and promoting an antibody response [153] ",potential,True,True,0,0,0,1.0,treated
2895,3154,24c20b8ab487acad45bb797b2ae0a2a910b31043,acetaminophen,body,10.1155/2012/236345,Eicosanoids and Respiratory Viral Infection: Coordinators of Inflammation and Potential Therapeutic Targets,2012.0,"Human volunteers challenged with RV showed increased nasal symptoms and a suppressed serum neutralizing antibody response when treated with aspirin or acetaminophen, suggesting a protective role for COX products in reducing symptoms and promoting an antibody response [153] ",potential,True,True,0,0,0,1.0,treated
3160,3446,26c6e83679b32d9574a757d4ca533ed4aa442ffa,testosterone,body,10.1016/b978-1-4557-0090-5.00063-x,61 Alternative vaccine delivery methods,2013.0,"Novel methods to deliver antigen into the skin Various commercial patch delivery systems developed since 1981 have demonstrated the ability of certain therapeutic agents (eg, scopolamine, nitroglycerin, clonidine, estradiol, fentanyl, nicotine, testosterone) to diffuse passively into bare, untreated skin without the use of the active technologies or enhancers described in the following paragraphs",,True,False,1,1,0,0.0,therapeutic
3208,3503,27a606f3c89e21ba2b287011593ed80b86a32113,acetate,body,10.1016/j.jneuroim.2008.08.001,8th Course of the European School of Neuroimmunology,2008.0,"Indeed, we found synergy between MTA and Glatiramer acetate, since suboptimal dosage combination of both drugs efficiently suppressed the disease",,True,True,0,0,0,0.0,suppress
3209,3504,27a606f3c89e21ba2b287011593ed80b86a32113,glatiramer,body,10.1016/j.jneuroim.2008.08.001,8th Course of the European School of Neuroimmunology,2008.0,"Indeed, we found synergy between MTA and Glatiramer acetate, since suboptimal dosage combination of both drugs efficiently suppressed the disease",,True,True,0,0,0,0.0,suppress
3210,3505,27a606f3c89e21ba2b287011593ed80b86a32113,acetate,body,10.1016/j.jneuroim.2008.08.001,8th Course of the European School of Neuroimmunology,2008.0,"Murine interferon beta (IFNbeta) and Glatiramer acetate, as well as MTA were administered i.p",,True,True,0,0,0,0.0,administer
3211,3506,27a606f3c89e21ba2b287011593ed80b86a32113,glatiramer,body,10.1016/j.jneuroim.2008.08.001,8th Course of the European School of Neuroimmunology,2008.0,"Murine interferon beta (IFNbeta) and Glatiramer acetate, as well as MTA were administered i.p",,True,True,0,0,0,0.0,administer
3212,3507,27a606f3c89e21ba2b287011593ed80b86a32113,acetate,body,10.1016/j.jneuroim.2008.08.001,8th Course of the European School of Neuroimmunology,2008.0,"Glatiramer acetate (GA, Copaxone) is an immunomodulatory MS therapy that is believed to mediate its effects through Th1 to Th2 immune deviation",,True,True,0,0,0,0.0,therapy
3213,3508,27a606f3c89e21ba2b287011593ed80b86a32113,copaxone,body,10.1016/j.jneuroim.2008.08.001,8th Course of the European School of Neuroimmunology,2008.0,"Glatiramer acetate (GA, Copaxone) is an immunomodulatory MS therapy that is believed to mediate its effects through Th1 to Th2 immune deviation",,True,True,0,0,0,0.0,therapy
3214,3509,27a606f3c89e21ba2b287011593ed80b86a32113,glatiramer,body,10.1016/j.jneuroim.2008.08.001,8th Course of the European School of Neuroimmunology,2008.0,"Glatiramer acetate (GA, Copaxone) is an immunomodulatory MS therapy that is believed to mediate its effects through Th1 to Th2 immune deviation",,True,True,0,0,0,0.0,therapy
3224,3519,27a606f3c89e21ba2b287011593ed80b86a32113,acetate,body,10.1016/j.jneuroim.2008.08.001,8th Course of the European School of Neuroimmunology,2008.0,"We have also shown that untreated MS patients show an overall deficit in the immune suppressive ability of CD8+ T-cells, which is corrected following glatiramer acetate (Copaxone) therapy.",,True,True,0,0,0,0.0,therapy
3225,3520,27a606f3c89e21ba2b287011593ed80b86a32113,glatiramer,body,10.1016/j.jneuroim.2008.08.001,8th Course of the European School of Neuroimmunology,2008.0,"We have also shown that untreated MS patients show an overall deficit in the immune suppressive ability of CD8+ T-cells, which is corrected following glatiramer acetate (Copaxone) therapy.",,True,True,0,0,0,0.0,therapy
3706,4034,2e2bc679c8393230bac2af64115bab7ed1ba62c0,acetaminophen,body,10.1186/cc8514,Large-scale implementation of a critical care surge capacity management program,2010.0,"Results Eighty-fi ve patients were treated, acetaminophen was the dominant aetiology in the UK, 60%, and represented 34% in other centres",,False,False,0,0,0,0.0,treated
3933,4302,300dee5bb71d6b2f7299e61366ae273ef7fc2735,dextrose,body,10.1016/s0749-0720(15)30161-4,Intravenous Fluid Therapy of Calves,1999.0,"In summary, veterinarians need only four types of intravenous solutions for treating calves: acetated Ringer's, isotonic sodium bicarbonate, hypertonic saline, and dextrose solution",,True,True,0,0,0,0.0,treating
3976,4345,3053529090a8974edc1ad695d3be4d407eef9674,testosterone,abstract,10.1186/s12983-018-0254-0,"Two predominant MUPs, OBP3 and MUP13, are male pheromones in rats",2018.0,"PGCL1), in urine and their mRNAs in liver were higher in males than in females and were suppressed by orchidectomy and restored by testosterone treatment (T treatment)",,False,False,0,0,0,0.0,treatment
4246,4636,3445833039239ebe203a2ff28ccb54c78cc57b6b,acetate,body,10.1053/j.tcam.2008.12.004,Pharmacologic Advances in Canine and Feline Reproduction,2009.0,"161 Many agents have been used to treat BPH including estrogenic compounds (estradiol cypionate, diethylstilbestrol) and synthetic progestins (megestrol acetate, medroxyprogesterone)",possible,True,True,0,0,0,0.0,treat
4267,4658,3445833039239ebe203a2ff28ccb54c78cc57b6b,acepromazine,body,10.1053/j.tcam.2008.12.004,Pharmacologic Advances in Canine and Feline Reproduction,2009.0,"Further small doses of opioid analgesics (codeine, morphine, fentanyl) or acepromazine may be administered to maintain pain relief and limit anxiety and stress",may,True,True,0,0,0,0.0,administered
4487,4885,36c123eb9cf765e87991924a21da9bdf32e7dc85,acetaminophen,abstract,10.1186/s13256-018-1764-2,The challenges of treating tracheobronchitis in a laryngectomee due to nontypeable Haemophilus influenzae: a case report,2018.0,"He was treated with levofloxacin 500 mg/day, ciprofloxacin eye drops, acetaminophen, and guaifenesin",,True,True,0,0,0,0.0,treated
4492,4890,36c123eb9cf765e87991924a21da9bdf32e7dc85,acetaminophen,body,10.1186/s13256-018-1764-2,The challenges of treating tracheobronchitis in a laryngectomee due to nontypeable Haemophilus influenzae: a case report,2018.0,"He was treated with orally administered levofloxacin 500 mg/day, ciprofloxacin eye drops, acetaminophen, and guaifenesin",,True,True,0,0,0,0.0,treated
4493,4891,36c123eb9cf765e87991924a21da9bdf32e7dc85,acetaminophen,body,10.1186/s13256-018-1764-2,The challenges of treating tracheobronchitis in a laryngectomee due to nontypeable Haemophilus influenzae: a case report,2018.0,"He was treated with orally administered levofloxacin 500 mg/day, ciprofloxacin eye drops, acetaminophen, and guaifenesin",,True,True,0,0,0,0.0,treated
4742,5159,39ae1255bf578428f00dcdb5422846fc94ce1c22,abciximab,body,10.1378/chest.10-1971,Beyond Thrombosis The Versatile Platelet in Critical Illness,2011.0,"72 On the other hand, abciximab (ReoPro), a chimeric Fab fragment of a monoclonal antibody with high affi nity for the GP IIb/IIIa receptor, was found to suppress the usual rise in levels of circulating infl ammatory markers following percutaneous transluminal coronary angioplasty",could,True,False,0,0,0,0.0,suppress
4982,5411,3d94191ac055bee08581038e9423511bd066b74c,amoxicillin,body,10.1016/b978-0-323-39956-2.00001-7,1 Sore Throat,2018.0,Treat as acute GAS pharyngitis with amoxicillin or penicillin (or an alternative agent) each time a test is positive; this will prevent ARF if the GAS identified has been newly acquired,,False,False,0,0,0,0.0,treat
4983,5412,3d94191ac055bee08581038e9423511bd066b74c,amoxicillin,body,10.1016/b978-0-323-39956-2.00001-7,1 Sore Throat,2018.0,It is preferable to treat most patients with penicillin or amoxicillin whenever symptomatic GAS pharyngitis occurs,,False,False,0,0,0,0.0,treat
5601,6070,44e49ea1e947840f56d464cc9926a0eac3e23b2d,abatacept,body,10.1007/s10875-019-00597-5,2019 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference,2019.0,"Our patient is currently undergoing therapy with abatacept (CTLA-4 fusion protein), which has been reported to improve GLILD, splenomegaly and enteropathy in patients with CTLA-4 haploinsufficiency",potential,True,True,0,0,0,0.0,therapy
5637,6106,4519998f22e00e318090334979b5d837a0e10da4,acetaminophen,body,10.1016/s0091-6749(98)70127-7,Sinusitis in the common cold,1998.0,"In subjects with fever or pain, acetaminophen therapy was permitted",,True,True,0,0,0,0.0,therapy
5681,6163,46030e9b8451bf3b0c90833dbeacce286a263a09,testosterone,body,10.1101/265199,An Augmented Aging Process in Brain White Matter in HIV,2018.0,"Participants were assigned a '1' if they endorsed a history of each of the following medical conditions: cerebrovascular risk factors including hypertension, heart failure, COPD, anemia, diabetes; endocrine dysfunction including thyroid disease, testosterone therapy, estrogen therapy; kidney disease",,False,False,0,0,0,0.0,therapy
5682,6164,46030e9b8451bf3b0c90833dbeacce286a263a09,testosterone,body,10.1101/265199,An Augmented Aging Process in Brain White Matter in HIV,2018.0,"Participants were assigned a '1' if they endorsed a history of each of the following medical conditions: cerebrovascular risk factors including hypertension, heart failure, COPD, anemia, diabetes; endocrine dysfunction including thyroid disease, testosterone therapy, estrogen therapy; kidney disease",,False,False,0,0,0,0.0,therapy
5774,6262,46e88010c4a926b35d981984c673bb834c17f7d2,cefepime,body,10.1590/s1806-37562018000000130,2018 recommendations for the management of community acquired pneumonia,2018.0,"(63) Recently, a study of a new cephalosporin, ceftaroline, demonstrated the superiority of ceftriaxone over ceftriaxone for the treatment of pneumococcal pneumonia",,True,False,0,0,0,0.0,treatment
5775,6263,46e88010c4a926b35d981984c673bb834c17f7d2,cefotaxime,body,10.1590/s1806-37562018000000130,2018 recommendations for the management of community acquired pneumonia,2018.0,"(63) Recently, a study of a new cephalosporin, ceftaroline, demonstrated the superiority of ceftriaxone over ceftriaxone for the treatment of pneumococcal pneumonia",,True,False,0,0,0,0.0,treatment
6021,6530,4a94f3fe57da5dad4c965d59faf0facc2039175a,acam2000,body,10.1371/journal.pone.0149364,Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines,2016.0,"The current US-licensed secondgeneration smallpox vaccine, ACAM2000, is also administered by skin scarification, a procedure that is believed to be partly responsible for the success of the global eradication of smallpox by provoking robust innate and adaptive immune responses [62] ",,False,False,0,0,0,0.0,administer
6362,6895,4fa899cfc3a16a61f3f33a66eb381d924c34cac9,tetracycline,body,10.1016/b978-1-4160-4390-4.00001-1,1 Tropical Lung Diseases,2013.0,"Antibiotics (ampicillin, tetracycline and sulfa drugs) are available to treat COPD exacerbations in the tropics.",,True,False,0,0,0,0.0,treat
6363,6896,4fa899cfc3a16a61f3f33a66eb381d924c34cac9,benzylpenicillin,body,10.1016/b978-1-4160-4390-4.00001-1,1 Tropical Lung Diseases,2013.0,"In severe pneumonia in hospitalized children, the policy in low-income countries is to first give benzylpenicillin injections, changing the therapy to oral amoxicillin when the child responds",potential,True,False,0,0,0,0.0,therapy
6551,7093,51b220c3b371a1f913a724037ada63579d016a4b,acetazolamide,body,10.1016/b978-0-323-35775-3.00015-1,Chapter 15 Skeletal Muscle 1,2017.0,"More severe cases can be treated with the diuretic acetazolamide, which causes increased urinary excretion of potassium",,True,False,0,0,0,0.0,treated
6556,7098,51b220c3b371a1f913a724037ada63579d016a4b,acetate,body,10.1016/b978-0-323-35775-3.00015-1,Chapter 15 Skeletal Muscle 1,2017.0,"Glucocorticoids with high mineralocorticoid activity, such as isoflupredone acetate used to treat ketosis, are a recognized cause of hypokalemic myopathy in cattle",may,True,False,0,0,0,0.0,treat
6620,7164,5206bbfc99d29f0573e944398e5c0a36aac097b2,acetaminophen,body,10.1016/b978-0-12-801238-3.66161-5,Respiratory Viruses,2019.0,No treatments are licensed although acetaminophen or ibuprofen are often used for treating fever,,True,True,0,0,0,0.0,treating
6654,7200,528411eebd9d3c1b16ab5ec425724551e7837c5d,acetate,body,10.1002/ccr3.1018,Hydrocortisone therapy in a cat with vasopressorâ€refractory septic shock and suspected critical illnessâ€related corticosteroid insufficiency,2017.0,"Heat cycle control with megestrol acetate (MA, 5 mg/cat PO every other week, in irregular intervals) was last administered 2 months earlier",,True,True,0,0,0,0.0,administered
6668,7215,529fe033afc5b8f83c55aa6b8f034fd506bf7b9b,acetate,body,10.1016/b978-044450514-9/50007-3,VII Digestive System 1,2000.0,"Adenomatous polyps have also been reported in the pyloric antrum of C57Bl/ 10J mice treated for 52 weeks with the synthetic progestin, cyproterone acetate (Tucker et al., 1996) ",,True,True,0,0,0,1.0,treated
6781,7335,54465e7a0e79e263ce5748574a53b1281e40b8b7,acetate,body,10.1007/s11064-010-0318-9,Glial Cell Lines: An Overview,2010.0,It is interesting to note that this study demonstrated a differential effect of treating the OLN-93 cells with two drugs prescribed as therapy for multiple sclerosis: a glucocorticoid (inhibited nitric oxide production) and Glatiramer Acetate (no effect on nitric oxide production) [12] .,,True,False,1,1,0,0.0,prescribed
6782,7336,54465e7a0e79e263ce5748574a53b1281e40b8b7,acetate,body,10.1007/s11064-010-0318-9,Glial Cell Lines: An Overview,2010.0,It is interesting to note that this study demonstrated a differential effect of treating the OLN-93 cells with two drugs prescribed as therapy for multiple sclerosis: a glucocorticoid (inhibited nitric oxide production) and Glatiramer Acetate (no effect on nitric oxide production) [12] .,,True,False,1,1,0,0.0,prescribed
6783,7337,54465e7a0e79e263ce5748574a53b1281e40b8b7,acetate,body,10.1007/s11064-010-0318-9,Glial Cell Lines: An Overview,2010.0,It is interesting to note that this study demonstrated a differential effect of treating the OLN-93 cells with two drugs prescribed as therapy for multiple sclerosis: a glucocorticoid (inhibited nitric oxide production) and Glatiramer Acetate (no effect on nitric oxide production) [12] .,,True,False,1,1,0,0.0,prescribed
6784,7338,54465e7a0e79e263ce5748574a53b1281e40b8b7,glatiramer,body,10.1007/s11064-010-0318-9,Glial Cell Lines: An Overview,2010.0,It is interesting to note that this study demonstrated a differential effect of treating the OLN-93 cells with two drugs prescribed as therapy for multiple sclerosis: a glucocorticoid (inhibited nitric oxide production) and Glatiramer Acetate (no effect on nitric oxide production) [12] .,,True,False,1,1,0,0.0,prescribed
6785,7339,54465e7a0e79e263ce5748574a53b1281e40b8b7,glatiramer,body,10.1007/s11064-010-0318-9,Glial Cell Lines: An Overview,2010.0,It is interesting to note that this study demonstrated a differential effect of treating the OLN-93 cells with two drugs prescribed as therapy for multiple sclerosis: a glucocorticoid (inhibited nitric oxide production) and Glatiramer Acetate (no effect on nitric oxide production) [12] .,,True,False,1,1,0,0.0,prescribed
6786,7340,54465e7a0e79e263ce5748574a53b1281e40b8b7,glatiramer,body,10.1007/s11064-010-0318-9,Glial Cell Lines: An Overview,2010.0,It is interesting to note that this study demonstrated a differential effect of treating the OLN-93 cells with two drugs prescribed as therapy for multiple sclerosis: a glucocorticoid (inhibited nitric oxide production) and Glatiramer Acetate (no effect on nitric oxide production) [12] .,,True,False,1,1,0,0.0,prescribed
6882,7440,5589f09fd26e12ead3a4d85c63396f3ba964a437,acetaminophen,body,10.1016/b978-032304841-5.50082-0,Chapter 80 Use of Blood Components in the Intensive Care Unit,2008.0,Antipyretics such as acetaminophen may be administered,,False,False,0,0,0,0.0,administered
6982,7557,57456a3b02f9debc020ba48ab5b731a3021853c2,acetaminophen,body,10.1016/b978-1-4557-0306-7.00115-x,Chapter 115 Hepatitis and Cholangiohepatitis,2015.0,S-Adenosylmethionine (SAMe) (20 mg/kg PO q24h) has been effective in treating acetaminophen toxicity,may,True,False,0,0,0,1.0,treating
7003,7582,575878920f54c7e5b25eb200434c0e769661dc30,acetaminophen,body,10.1016/b978-0-323-35868-2.00018-9,Chapter 18 Viral Upper Respiratory Infection,2018.0,"There is no doubt that acetaminophen and nonsteroidal antiinflammatories (NSAIDs), such as aspirin, ibuprofen, and naproxen, are effective in treating pain and fever that may accompany the common cold",,True,False,1,1,0,0.0,treating
7347,7962,5d9bcd526f7f5ea2052abc6aa7d33862b9460c2e,sofosbuvir,body,10.1016/b978-0-323-44585-6.00011-4,11 Liver and Bile Duct Infections,2018.0,"63 Sofosbuvir is the first NS5B NPI available in the United States and has become the backbone of HCV therapy given its high barrier to resistance, pangenotypic activity, and favorable pharmacologic profile",possible,True,False,0,0,0,0.0,therapy
7348,7963,5d9bcd526f7f5ea2052abc6aa7d33862b9460c2e,pentamidine,body,10.1016/b978-0-323-44585-6.00011-4,11 Liver and Bile Duct Infections,2018.0,"Extrapulmonary infection is rare but has been associated with the use of prophylactic aerosolized pentamidine, which suppresses pulmonary disease but might allow for dissemination of the organism",,True,False,0,0,0,1.0,suppress
7349,7964,5d9bcd526f7f5ea2052abc6aa7d33862b9460c2e,aspirin,body,10.1016/b978-0-323-44585-6.00011-4,11 Liver and Bile Duct Infections,2018.0,"In children, the convalescent phase can be associated with Reye syndrome (microvesicular steatosis, hyperammonemia, coagulopathy, and cerebral edema), particularly if aspirin has been administered",potential,True,False,0,0,0,1.0,administer
7350,7967,5d9bcd526f7f5ea2052abc6aa7d33862b9460c2e,ribavirin,body,10.1016/b978-0-323-44585-6.00011-4,11 Liver and Bile Duct Infections,2018.0,The addition of ribavirin (RBV) to peg-IFN improved SVR rates and became the mainstay of therapy,possible,True,False,0,0,0,0.0,improved
7497,8124,5ed162916c24882e7936eb2347757374a81402c0,ciprofloxacin,body,10.1016/b978-0-12-801885-9.00010-x,10 Select agent program impact on the IBC,2016.0,"These countermeasures may include vaccinations or plans for provision of therapeutic treatments, such as oseltamivir or ciprofloxacin, should there be a high level of suspicion of the possibility of exposure",potential,True,False,0,0,0,0.0,treatment
7498,8125,5ed162916c24882e7936eb2347757374a81402c0,oseltamivir,body,10.1016/b978-0-12-801885-9.00010-x,10 Select agent program impact on the IBC,2016.0,"These countermeasures may include vaccinations or plans for provision of therapeutic treatments, such as oseltamivir or ciprofloxacin, should there be a high level of suspicion of the possibility of exposure",potential,True,False,0,0,0,0.0,treatment
7896,8559,60ed0c88c9c6f930b9a95bb7743380519370c7f4,acepromazine,body,10.1016/b0-72-160138-3/50002-3,Section 1 Emergency Care,2006.0,"Administer the anxiolytic tranquilizer acepromazine (0.02-0.05 mg/kg IV, IM, SQ) to decrease patient anxiety",,True,True,0,0,0,0.0,Administer
8459,9162,64d44f11ef92426fc34085a407dac52e8b051dc7,acetaminophen,body,10.1016/j.medcle.2016.10.022,Zika virus infection or the future of infectious diseases,2016.0,"40 We have no direct action antiviral treatment or any treatment that may limit its transmission; fever can be treated with acetaminophen to start with, and NSAIDs can be reserved for patients with joint involvement, provided dengue had been ruled out, otherwise the risk of bleeding may be enhanced.",,False,False,1,1,0,0.0,treated
8574,9289,66b67940ae16f657fd93fad230081d20d98c55f7,lopinavir,body,10.1093/pcmedi/pbaa002,A precision medicine approach to managing Wuhan Coronavirus pneumonia,2020.0,"(a) Bed rest, supporting treatment, and monitoring vital signs; (b) Routine laboratory tests for blood and urine, C-reactive protein, serum biochemical indexes, and coagulation function; (c) Antiviral therapies with atomized inhalation of Î±interferon and lopinavir or ritonavir in suitable patients; (d) Avoid inappropriate and blind administration of antibiotics, especially broad-spectrum antibiotics",,True,True,0,0,0,0.0,therapies
8575,9290,66b67940ae16f657fd93fad230081d20d98c55f7,ritonavir,body,10.1093/pcmedi/pbaa002,A precision medicine approach to managing Wuhan Coronavirus pneumonia,2020.0,"(a) Bed rest, supporting treatment, and monitoring vital signs; (b) Routine laboratory tests for blood and urine, C-reactive protein, serum biochemical indexes, and coagulation function; (c) Antiviral therapies with atomized inhalation of Î±interferon and lopinavir or ritonavir in suitable patients; (d) Avoid inappropriate and blind administration of antibiotics, especially broad-spectrum antibiotics",,True,True,0,0,0,0.0,therapies
8833,9567,68a7101a90454172c91785d8c352f776a82df5d4,acetate,body,10.1016/j.jneuroim.2010.08.001,"ISNI 2010 Abstracts Tuesday October 26th, 2010 10th Course of the European School of Neuroimmunology",2010.0,Glatiramer acetate (GA) therapy in multiple sclerosis (MS) is considered to lead to systemic alterations in circulating monocytes,could,True,False,0,0,0,0.0,therapy
8834,9568,68a7101a90454172c91785d8c352f776a82df5d4,glatiramer,body,10.1016/j.jneuroim.2010.08.001,"ISNI 2010 Abstracts Tuesday October 26th, 2010 10th Course of the European School of Neuroimmunology",2010.0,Glatiramer acetate (GA) therapy in multiple sclerosis (MS) is considered to lead to systemic alterations in circulating monocytes,could,True,False,0,0,0,0.0,therapy
8849,9583,68a7101a90454172c91785d8c352f776a82df5d4,acetate,body,10.1016/j.jneuroim.2010.08.001,"ISNI 2010 Abstracts Tuesday October 26th, 2010 10th Course of the European School of Neuroimmunology",2010.0,"The therapeutic effect of Glatiramer acetate (GA, CopaxoneÃ¢) has been attributed to immunomodulation from inflammatory towards anti-inflammatory pathway",,True,False,0,0,0,0.0,effect
8850,9584,68a7101a90454172c91785d8c352f776a82df5d4,glatiramer,body,10.1016/j.jneuroim.2010.08.001,"ISNI 2010 Abstracts Tuesday October 26th, 2010 10th Course of the European School of Neuroimmunology",2010.0,"The therapeutic effect of Glatiramer acetate (GA, CopaxoneÃ¢) has been attributed to immunomodulation from inflammatory towards anti-inflammatory pathway",,True,False,0,0,0,0.0,effect
8857,9592,68a7101a90454172c91785d8c352f776a82df5d4,acetate,body,10.1016/j.jneuroim.2010.08.001,"ISNI 2010 Abstracts Tuesday October 26th, 2010 10th Course of the European School of Neuroimmunology",2010.0,"Aims: To investigate the expression of P2X7R, IL-1beta and ectoapyrase CD39 on peripheral blood monocytes of MS patients and to see whether Glatiramer Acetate (GA) therapeutic effects in MS may be possibly mediated by mechanisms interfering with the ATP/P2X7R interaction and hence with the induction of IL-1beta or with the ATP activity modulating CD39",may,True,False,0,0,0,0.0,therapeutic
8858,9593,68a7101a90454172c91785d8c352f776a82df5d4,glatiramer,body,10.1016/j.jneuroim.2010.08.001,"ISNI 2010 Abstracts Tuesday October 26th, 2010 10th Course of the European School of Neuroimmunology",2010.0,"Aims: To investigate the expression of P2X7R, IL-1beta and ectoapyrase CD39 on peripheral blood monocytes of MS patients and to see whether Glatiramer Acetate (GA) therapeutic effects in MS may be possibly mediated by mechanisms interfering with the ATP/P2X7R interaction and hence with the induction of IL-1beta or with the ATP activity modulating CD39",may,True,False,0,0,0,0.0,therapeutic
8912,9651,69eb6f3994e9038a39895bc685be0d3aac1c2746,acetaminophen,body,10.1016/j.jpeds.2016.05.025,Nonsteroidal Anti-Inflammatory Drug without Antibiotics for Acute Viral Infection Increases the Empyema Risk in Children: A Matched Case-Control Study,2016.0,"Acetaminophen also was prescribed more frequently for cases than controls, particularly when taken for at least 3 consecutive days (Table III) .",,False,False,0,0,0,0.0,prescribed
8943,9685,6a699211ba4c73887c906f8888d52912c626d09a,amantadine,body,,,,(2002) have used a highly neurovirulent recombinant R404BP strain of influenza A (H1N1) virus to test amantadine therapy in mice,,False,False,0,0,0,0.0,therapy
8958,9700,6aadca94314fe7e81e278fbbef178f2a5bf4f538,acetaminophen,body,10.1186/cc13531,Lower airway sampling greatly increases detection of respiratory viruses in critically ill patients: the COURSE study,2014.0,Reference Introduction Acetaminophen (APAP) is commonly administered in the surgical ICU (SICU) for its analgesic and antipyretic eff ects,,False,False,0,0,0,0.0,administer
9074,9830,6bcf5a5f877be9a08113db6aec4a409f8d111895,acetaminophen,body,10.1186/1752-1947-5-520,Respiratory failure presenting in H1N1 influenza with Legionnaires disease: two case reports,2011.0,"Acetaminophen, ketorolac, levofloxacin and normal saline were administered.",,False,False,0,0,0,0.0,administered
9143,9905,6cd83be7f164f219a52ec861871c77790da19acd,testosterone,body,10.1016/b978-0-12-374279-7.19001-0,Immunity and the Endocrine System,2016.0,"The adaptive immune response is also suppressed by testosterone, mirrored by a reduced T cell proliferation and cytokine production (Olsen and Kovacs, 1996) , a lower proliferation of immature thymocytes, and accelerated thymic apoptosis (McMurray et al., 2001) , thereby inducing thymic atrophy (Chang et al., 2013; Olsen et al., 1991) ",,True,True,0,0,0,0.0,suppressed
9325,10093,6ebbce608cb316b579ed926190d068a6fa90534a,vancomycin,body,10.1186/s12931-016-0479-4,â€˜The Microbiome and the Pathophysiology of Asthmaâ€™,2016.0,"To test the effect of early life antibiotic exposure to the microbiota and subsequent allergic asthma susceptibility Russell et al., treated neonatal mice with clinical doses of Vancomycin and Streptomycin",could,True,False,0,0,0,0.0,treated
9462,10249,70fefc54856d09f01cb983932a860dc4dacb9f46,acacia,body,10.3892/ijmm.2012.1096,Curcumin inhibits HCV replication by induction of heme oxygenase-1 and suppression of AKT,2012.0,"In certain reports, the inhibition of NF-ÎºB shows anti-HCV activity: for example, the Acacia confusa (61) and San-Huang-Xie-Xin-Tang extracts (62) suppress HCV replication associated with NF-ÎºB inhibition",,True,True,0,0,0,0.0,suppress
9478,10268,715fec9052e391ea2d2bd055e7fea736b2882bc7,testosterone,body,,In vitro macrophage manifestation of cortisone-induced decrease in resistance to mouse hepatitis virus,1981.0,Two steroids (progesterone and testosterone) were similarly administered,,False,False,0,0,0,0.0,administer
10090,10930,78814db48e430f67f1471d04c588beebc128fa19,acetate,body,10.1016/b978-0-7216-7665-4.50015-2,Chapter 11 The Liver and Pancreas,2001.0,"If o-penicillamine is not tolerated, another copper chelator, 2,3,2-trientine, administered at 10 to 15 mg/kg orally one to two times daily or zinc acetate administered at 50 to 200 mg orally once a day, decreases intestinal absorption of copper and may be used",may,True,False,1,1,0,0.0,administered
10091,10931,78814db48e430f67f1471d04c588beebc128fa19,acetate,body,10.1016/b978-0-7216-7665-4.50015-2,Chapter 11 The Liver and Pancreas,2001.0,"If o-penicillamine is not tolerated, another copper chelator, 2,3,2-trientine, administered at 10 to 15 mg/kg orally one to two times daily or zinc acetate administered at 50 to 200 mg orally once a day, decreases intestinal absorption of copper and may be used",may,True,False,1,1,0,0.0,administered
10136,10980,791afe1d829e56b23ce1f098c66cdb4fc4b1eb34,acetaminophen,body,10.1016/j.pcl.2005.06.002,Prevention of Travel-Related Infectious Diseases in Families of Internationally Adopted Children,2005.0,You may administer pediatric acetaminophen to control the temperature.,,False,False,0,0,0,0.0,administer
10141,10985,792417a1bbb50a19ce96e8354aa9f16f2424b850,acetate,body,10.1186/cc12073,High incidence of respiratory viruses in critically ill adult patients with respiratory failure,2013.0,"We collected for each patient the GBS, the blood lactate value on arrival in the ED, the blood lactate value after bolus administration of 20 to 40 ml/kg Ringer's acetate (initial fl uid therapy) and the report of urgent endoscopy",hypothesize,False,False,0,0,0,0.0,administration
10218,11067,79e75fc82b515edcb68d6c8a6b83d630e3b21193,acetate,body,10.1111/jvim.15473,Perspectives in veterinary medicine: Description and classification of bronchiolar disorders in cats,2019.0,The cat had been treated for psychogenic alopecia with megestrol and methylprednisolone acetate and subsequently developed mammary masses,potential,False,False,0,0,0,1.0,treated
10400,11263,7af37cc39c5f2eeb88b98ea439da7fc687eddb60,acepromazine,body,10.1051/vetres/2009028,In vivo transmission studies of â€˜Candidatus Mycoplasma turicensisâ€™ in the domestic cat,2009.0,"The cats were administered acepromazine (Arovet AG, Zollikon, Switzerland, 0.01 mg/kg) and buprenorphine (Essex Chemie, Switzerland, 0.01 mg/kg) intramuscularly, followed by an intravenous injection of propofol (Fresenius, Bad Homburg, Germany; induction 5 mg/kg; maintenance 1 mg/kg every 2 min)",,True,False,0,0,0,0.0,administered
10403,11266,7af37cc39c5f2eeb88b98ea439da7fc687eddb60,acetate,body,10.1051/vetres/2009028,In vivo transmission studies of â€˜Candidatus Mycoplasma turicensisâ€™ in the domestic cat,2009.0,"All three cats were administered two doses of methylprednisolone acetate intramuscularly (10 mg/kg, Depo-Medrol, Pfizer AG, Zurich, Switzerland) in an attempt to immunocompromise the cats; Cats X and Y were injected 16 and 9 days prior to CMt inoculation, Cat Z was injected 8 and 1 days prior to CMt inoculation",,True,False,0,0,0,1.0,administer
10433,11299,7bc902adee438abe3d23d51cb7223c90fe111867,acetaminophen,body,10.1016/b978-1-4160-4390-4.00134-x,134 Animals Hazardous to Humans,2013.0,Pain can be treated with oral acetaminophen or codeine phosphate,possible,True,False,0,0,0,0.0,treated
10446,11313,7bfcd661fcd1248cb3ecaeea416eee85a689bf32,acetate,body,10.1186/2045-3701-4-11,Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells,2014.0,"Briefly, female C57BL/6 mice were treated with 3 mg/ mouse of medroxyprogesterone acetate via subcutaneous injection",could,False,False,0,0,0,0.0,treated
10992,11896,83953a069758ba0518e840caf74440b678f3ad12,acetate,body,10.1016/b978-0-7020-2827-4.50017-6,Chapter 11 Diseases of special concern,2007.0,Chemical means to treat POA can be by megestrol acetate which has been used to delay oestrus but there may be a risk of pyometra,,True,False,0,0,0,0.0,treat
11019,11924,8410d35d9d6859a92202a79f76d77cb8e7ed69da,tetracycline,body,10.1016/b978-1-4557-4801-3.00104-1,104 Tropical Sprue Enteropathy,2015.0,Combination therapy with tetracycline and folate seems to be most effective in symptom resolution and cure of diarrhea with promotion of weight gain,,True,False,0,0,0,0.0,therapy
11020,11925,8410d35d9d6859a92202a79f76d77cb8e7ed69da,tetracycline,body,10.1016/b978-1-4557-4801-3.00104-1,104 Tropical Sprue Enteropathy,2015.0,Combination therapy with tetracycline and folate seems to be most effective in symptom resolution and cure of diarrhea with promotion of weight gain,,True,False,0,0,0,0.0,therapy
11109,12019,84880da41ed365501561a145b4596bc6509b5d6d,acetaminophen,body,10.1016/b978-0-323-44329-6.00007-3,Chapter 7 Clinical Approach to Commonly Encountered Problems,2018.0,"Also, Î±-MSH has significant antipyretic effects, being more effective in controlling fever than acetaminophen when administered to human beings",may,True,False,0,0,0,0.0,administered
11176,12088,84e4e7bfc31594ccc66e51123640ee64006c43a0,acetate,body,10.1016/j.cvex.2016.01.006,Medical and Surgical Emergencies in Ferrets,2016.0,"Human chorionic gonadotropin (100 IU) Medroxyprogesterone (15 mg) Proligestone (40 mg) Gonadotropin-releasing hormone (GnRH; 20 mg/kg) Long-term depot GnRH agonists (4.7 mg deslorelin acetate [Suprelorin, Virbac]) Hyperestrogenism from adrenal hyperplasia or neoplasia Current therapies for adrenal disease in ferrets include medical and/or surgical treatment",,True,False,0,0,0,0.0,therapies
11309,12232,8607aac9046864becdec9a89df48524d61192e09,acetate,body,10.3390/v12010026,A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice,2019.0,"Nonstimulated cells were used as a mock control, and the positive controls cultures were treated with phorbol myristate acetate (PMA) and ionomycin (both from Sigma-Aldrich) or vaccinia virus (VACV)-specific CD8 T cell epitope, B8R 20-27 (TSYKFESV) [59] ",,False,False,0,0,0,0.0,treated
11315,12238,862dbb7e5c850f946575d3c882f46be61d139a22,acetate,body,10.1016/j.jff.2013.04.018,Bioactive principles from Cordyceps sinensis: A potent food supplement â€“ A review,2013.0,"Crystallized preparation of CS (Cs-Cr) could cause significant elevation of T helper cells and Lyt-1/Lyt-2 (T helper to T suppressor cell) ratio both in peripheral blood and the treated mice spleen and also could provide protection against immunosuppressive effects of prednisolone acetate and cyclophosphamide to T helper cells (Chen, Chen, Sun, Hsieh, & Henshall, 1991) ",,False,False,0,0,0,1.0,effect
11323,12246,86350f9291fa5cbf03bb638e3d4c62e543334113,acetaminophen,body,10.1016/s0095-4543(05)70355-9,THE COMMON COLD,1996.0,Aspirin and acetaminophen suppress the serum antibody response but increase nasal symptoms and signs,,False,False,0,0,0,1.0,suppress
11725,12674,8a541d5535412574cecb9a7bf5489e569896d15c,testosterone,body,10.1016/s0147-9571(01)00033-9,The effect of immunosuppression on protective immunity of turkey poults against infection with turkey coronavirus,2002.0,"The protective role of B cells against IBV infections has been shown by selective experimental suppression with the chemical CY, the hormone testosterone propionate, or surgical bursectomy [10] ",may,True,True,0,0,0,0.0,suppression
11809,12761,8baba2afe8dd478ae1d7ed13b666098aa3bfb623,acetaminophen,body,10.3201/eid1002.030736,SARS and Pregnancy: A Case Report,2004.0,"The next morning, she sought medical attention and was prescribed chlorpheniramine and acetaminophen",,True,True,0,0,0,0.0,prescribe
11902,12861,8c55bcbbc026105e30552c1c955cabef0bffcdba,acetate,body,10.1016/j.msard.2018.09.035,Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application,2019.0,"In particular, immune-modulatory therapies, such as IFN-Î², glatiramer acetate or teriflunomide, could impact the low circulating level of TÎ±1 and/or TÎ²4 in MS patients",may,False,False,0,0,0,0.0,therapies
11904,12863,8c55bcbbc026105e30552c1c955cabef0bffcdba,glatiramer,body,10.1016/j.msard.2018.09.035,Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application,2019.0,"In particular, immune-modulatory therapies, such as IFN-Î², glatiramer acetate or teriflunomide, could impact the low circulating level of TÎ±1 and/or TÎ²4 in MS patients",may,False,False,0,0,0,0.0,therapies
11907,12866,8c55bcbbc026105e30552c1c955cabef0bffcdba,teriflunomide,body,10.1016/j.msard.2018.09.035,Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application,2019.0,"In particular, immune-modulatory therapies, such as IFN-Î², glatiramer acetate or teriflunomide, could impact the low circulating level of TÎ±1 and/or TÎ²4 in MS patients",may,False,False,0,0,0,0.0,therapies
12250,13232,8f9f22f0d245cf41e5047230fa1c907b47a734ac,tiotropium,body,10.3389/fmicb.2013.00293,Virus-induced exacerbations in asthma and COPD,2013.0,(2012) reported that additive long-acting muscarinic antagonist (LAMA) therapy with tiotropium (known as a cornerstone of COPD treatment) significantly increased the time to the first exacerbation and improved FEV 1.0 in poorly controlled asthmatic patients with standard therapy (ICS and LABA),,True,True,0,0,0,0.0,therapy
12313,13302,9065cdc11c25a2c43a477b383a60123ecb9b6d39,cortisone,body,10.1016/s0580-9517(08)70679-2,1 Management of Immunocompromised and Infected Animals,1998.0,"In the past, injection of cortisone to suppress the immune system was recommended",may,False,False,0,0,0,0.0,suppress
12357,13351,91065d913a0f1e98aa955ca5600501e0054af28a,acetaminophen,body,10.1016/b0-72-169777-1/50005-6,Chapter 3 Clinical Approach to Commonly Encountered Problems,2004.0,"[16] [17] [18] [19] When administered to human beings, Î±-melanocyte-stimulating hormone is a much more potent antipyretic than acetaminophen",,True,False,0,0,0,0.0,administered
12527,13530,92ba217b7f08c2a514197da2fbfe46898e6f874e,acetate,body,10.1016/b978-0-444-62703-2.00007-0,Chapter 7 HHV-6 and Multiple Sclerosis,2014.0,"Relapsing and remitting MS patients are treated with a variety of disease-modifying agents, including interferon-Î³, glatiramer acetate, natalizumab, and fingolimod; these agents reduce the frequency of relapses but do not reverse the acquired deficits, and they have unclear effects on disease progression",may,True,False,1,1,0,0.0,treated
12528,13531,92ba217b7f08c2a514197da2fbfe46898e6f874e,fingolimod,body,10.1016/b978-0-444-62703-2.00007-0,Chapter 7 HHV-6 and Multiple Sclerosis,2014.0,"Relapsing and remitting MS patients are treated with a variety of disease-modifying agents, including interferon-Î³, glatiramer acetate, natalizumab, and fingolimod; these agents reduce the frequency of relapses but do not reverse the acquired deficits, and they have unclear effects on disease progression",may,True,False,1,1,0,0.0,treated
12529,13532,92ba217b7f08c2a514197da2fbfe46898e6f874e,glatiramer,body,10.1016/b978-0-444-62703-2.00007-0,Chapter 7 HHV-6 and Multiple Sclerosis,2014.0,"Relapsing and remitting MS patients are treated with a variety of disease-modifying agents, including interferon-Î³, glatiramer acetate, natalizumab, and fingolimod; these agents reduce the frequency of relapses but do not reverse the acquired deficits, and they have unclear effects on disease progression",may,True,False,1,1,0,0.0,treated
12530,13533,92ba217b7f08c2a514197da2fbfe46898e6f874e,natalizumab,body,10.1016/b978-0-444-62703-2.00007-0,Chapter 7 HHV-6 and Multiple Sclerosis,2014.0,"Relapsing and remitting MS patients are treated with a variety of disease-modifying agents, including interferon-Î³, glatiramer acetate, natalizumab, and fingolimod; these agents reduce the frequency of relapses but do not reverse the acquired deficits, and they have unclear effects on disease progression",may,True,False,1,1,0,0.0,treated
12565,13573,932bcdd2f6c6d487386e8bf983e4874387771be1,acetate,body,10.1016/j.jneuroim.2004.06.010,Abstract book of the 7th ISNI Congress,2004.0,Glatiramer acetate (Copaxone) therapy induces an oligoclonal CD8+ T cell response with cytotoxic ability R,,True,False,0,0,0,1.0,therapy
12682,13698,941f5d4642e7f16ebb3f3e6c7b2429eaa8464544,acetate,body,10.1016/j.bbadis.2009.07.002,Is multiple sclerosis a mitochondrial disease?,2010.0,"More importantly, EAE has led directly to the development of three therapies approved for use in MS: glatiramer acetate (copaxone), mitoxantrone, and natalizumab [103] ",may,True,False,0,0,0,0.0,therapies
12683,13699,941f5d4642e7f16ebb3f3e6c7b2429eaa8464544,glatiramer,body,10.1016/j.bbadis.2009.07.002,Is multiple sclerosis a mitochondrial disease?,2010.0,"More importantly, EAE has led directly to the development of three therapies approved for use in MS: glatiramer acetate (copaxone), mitoxantrone, and natalizumab [103] ",may,True,False,0,0,0,0.0,therapies
12684,13700,941f5d4642e7f16ebb3f3e6c7b2429eaa8464544,mitoxantrone,body,10.1016/j.bbadis.2009.07.002,Is multiple sclerosis a mitochondrial disease?,2010.0,"More importantly, EAE has led directly to the development of three therapies approved for use in MS: glatiramer acetate (copaxone), mitoxantrone, and natalizumab [103] ",may,True,False,0,0,0,0.0,therapies
12685,13701,941f5d4642e7f16ebb3f3e6c7b2429eaa8464544,natalizumab,body,10.1016/j.bbadis.2009.07.002,Is multiple sclerosis a mitochondrial disease?,2010.0,"More importantly, EAE has led directly to the development of three therapies approved for use in MS: glatiramer acetate (copaxone), mitoxantrone, and natalizumab [103] ",may,True,False,0,0,0,0.0,therapies
12745,13765,94d2ebfc7a2a0ffc00b05ce8031fdfef3255af4a,acetaminophen,body,10.1038/emi.2016.136,The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages,2017.0,"The patient was empirically treated for yellow fever with oral acetaminophen, an intravenous infusion of 5% glucose and a sodium chloride injection at a local hospital",,False,False,0,0,0,0.0,treated
13026,14058,968b6bc81a136025db5742ae8d6d0cee4f2eb2ce,testosterone,body,10.1016/j.pnpbp.2006.01.008,Human brain evolution and the â€œNeuroevolutionary Time-depth Principle:â€ Implications for the Reclassification of fear-circuitry-related traits in DSM-V and for studying resilience to warzone-related posttraumatic stress disorder,2006.0,"One of the ""phobia subtype-specific"" loci involved in bloodletting/injury fears may carry a developmentally sensitive gene (existing in a stable polymorphism) in which the expression mechanism is gradually suppressed by pleiotropic androgens such as dehydroxyepiandrosterone sulfate (DHEA-S) and testosterone",,False,False,0,0,0,1.0,suppress
13143,14182,97b72b50418604df9a684ceb2e05c040ec22b94d,acepromazine,body,10.1016/b978-1-4557-0892-5.00018-0,Chapter 18 Gastrointestinal System,2014.0,â€¢ Administer acepromazine (0.02 mg/kg IM q8h) for its vasodilatory properties,,True,True,0,0,0,0.0,Administer
13412,14473,9bbac1f67fbab1d4f3e9a20387a63989bf40bfad,acetate,body,10.3390/ijms131013438,Multiple Sclerosis: The Role of Cytokines in Pathogenesis and in Therapies,2012.0,"Since the early 1990s, disease-modifying drugs have been introduced for the selective MS management, including IFN-Î² and glatiramer acetate (GA), which have become the standard treatment for relapsing/remitting MS [89] but in this paragraph we analyze, in detail, three domains of novel immune-mediated therapeutics used for MS; the first domain includes immunosuppressive/immunomodulator agents, such as mitoxantrone, laquinimod (ABR-215062, cladribine (Mylinax), and teriflunomide",,False,False,0,0,0,0.0,treatment
13413,14474,9bbac1f67fbab1d4f3e9a20387a63989bf40bfad,glatiramer,body,10.3390/ijms131013438,Multiple Sclerosis: The Role of Cytokines in Pathogenesis and in Therapies,2012.0,"Since the early 1990s, disease-modifying drugs have been introduced for the selective MS management, including IFN-Î² and glatiramer acetate (GA), which have become the standard treatment for relapsing/remitting MS [89] but in this paragraph we analyze, in detail, three domains of novel immune-mediated therapeutics used for MS; the first domain includes immunosuppressive/immunomodulator agents, such as mitoxantrone, laquinimod (ABR-215062, cladribine (Mylinax), and teriflunomide",,False,False,0,0,0,0.0,treatment
13618,14689,9dd88265053594d2736a884a8b972b6ae94218c5,acetate,body,10.3390/v10120718,CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice,2018.0,"Non-stimulated cells and cells treated with phorbol myristate acetate (PMA) (SIGMA-ALDRICH) and ionomycin (SIGMA-ALDRICH, Taufkirchen, Germany) or MVA F2L [26] [27] [28] [29] [30] [31] [32] [33] [34] peptide (F2L, SPGAAGYDL, Thermo Fisher Scientific, Planegg, Germany) [49] served as negative and positive controls, respectively",,True,True,0,0,0,0.0,treated
13704,14783,9ecc8a7037f3dc24ea30161defcd84328dfaf835,acetate,body,10.1007/s11481-015-9614-0,Multiple Sclerosis and T Lymphocytes: An Entangled Story,2015.0,"More recently, CD8 T lymphocytes bearing the capacity to kill myelin specific CD4 T lymphocytes in a HLA-E restricted fashion were described (Correale and Villa 2008) especially in MS patients treated with glatiramer acetate, a synthetic copolymer of four amino acids (Tennakoon et al",,False,False,1,1,0,0.0,treated
13705,14784,9ecc8a7037f3dc24ea30161defcd84328dfaf835,glatiramer,body,10.1007/s11481-015-9614-0,Multiple Sclerosis and T Lymphocytes: An Entangled Story,2015.0,"More recently, CD8 T lymphocytes bearing the capacity to kill myelin specific CD4 T lymphocytes in a HLA-E restricted fashion were described (Correale and Villa 2008) especially in MS patients treated with glatiramer acetate, a synthetic copolymer of four amino acids (Tennakoon et al",,False,False,1,1,0,0.0,treated
13713,14794,9f2eacde02bfd34993a2eab9d87c2643fcfd17e2,abacavir,body,10.1186/1758-2652-7-2-71,Cytokine Profiles in Human Immunodeficiency Virus-Infected Children Treated With Highly Active Antiretroviral Therapy,2005.0,"Patients were started on HAART immediately after confirmation of HIV-1 infection and were treated with 2 nucleoside reverse transcriptase inhibitors (zidovudine, lamivudine, didanosine, stavudine, and/or abacavir) plus 1 protease inhibitor (indinavir, nelfinavir, Kaletra (lopinavir + ritonavir), ritonavir, or amprenavir) or the nonnucleoside reverse transcriptase inhibitor nevirapine",,False,False,0,0,0,0.0,treated
13960,15051,a0c4f2157df946bdd38d0ef78691787409588e37,acetaminophen,body,,,,"52 At the moment, the effects of other environmental exposures on the development of asthma remain controversial with respect to planning interventions, including the use of acetaminophen to treat fevers in young children, early childhood vaccines, and exposure to parasitic infections",may,True,False,0,0,0,0.0,treat
14074,15174,a190fd77c8432d20849ebf73d31446fd881ee1e7,idoxuridine,body,10.1016/b978-0-12-813374-3.00016-8,Chapter 16 Antiviral Evaluation of Herbal Drugs,2019.0,"(1962) , an ophthalmologist, successfully treated a herpes eye infection with an antineoplastic drug, Idoxuridine",,True,True,0,0,0,0.0,treated
14080,15180,a1c87584d25ea40e6845a0007fe09509bd111db0,acetate,body,10.1016/b978-0-12-800763-1.00004-x,Chapter 4 Role of CD4+ T Cells in the Pathophysiology of Multiple Sclerosis,2016.0,"Suppression of MS disease activities by immunomodulatory drugs, such as glatiramer acetate, has also been associated with enhanced Th2 immune responses (Weber et al., 2007) ",may,True,False,0,0,0,0.0,supression
14081,15181,a1c87584d25ea40e6845a0007fe09509bd111db0,glatiramer,body,10.1016/b978-0-12-800763-1.00004-x,Chapter 4 Role of CD4+ T Cells in the Pathophysiology of Multiple Sclerosis,2016.0,"Suppression of MS disease activities by immunomodulatory drugs, such as glatiramer acetate, has also been associated with enhanced Th2 immune responses (Weber et al., 2007) ",may,True,False,0,0,0,0.0,supression
14082,15182,a1c87584d25ea40e6845a0007fe09509bd111db0,acetate,body,10.1016/b978-0-12-800763-1.00004-x,Chapter 4 Role of CD4+ T Cells in the Pathophysiology of Multiple Sclerosis,2016.0,"Clinically, immunomodulatory drugs, such as IFN-Î², glatiramer acetate, and anti-very late antigen-4 antibody (Tysabri Â® (natalizumab)), have been shown to suppress the disease activity of RRMS patients ",,True,False,0,0,0,0.0,suppress
14083,15183,a1c87584d25ea40e6845a0007fe09509bd111db0,glatiramer,body,10.1016/b978-0-12-800763-1.00004-x,Chapter 4 Role of CD4+ T Cells in the Pathophysiology of Multiple Sclerosis,2016.0,"Clinically, immunomodulatory drugs, such as IFN-Î², glatiramer acetate, and anti-very late antigen-4 antibody (Tysabri Â® (natalizumab)), have been shown to suppress the disease activity of RRMS patients ",,True,False,0,0,0,0.0,suppress
14175,15279,a2e717e550d63d5519146d4b94fd7f71468e0a1a,acetaminophen,body,10.3201/eid2009.140378,"Family Cluster of Middle East Respiratory Syndrome Coronavirus Infections, Tunisia, 2013",2014.0,"One of his children (patient 3, a nurse) gave him acetaminophen and aspirin for 3 days and then intravenously administered dexamethasone (4 mg) twice a day for 2 days",,True,False,0,0,0,0.0,administer
14184,15291,a2f53651474ffa6ede94371fa2d2e735395d965e,acetaminophen,body,,,,"Study subjects may self administer medications such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), or antihistamines as required",may,False,False,0,0,0,0.0,administer
14204,15314,a33e3ade1bf2a47195051d6d458baa2001ab72a5,acetaminophen,body,10.1155/2013/746053,Prescription Surveillance and Polymerase Chain Reaction Testing to Identify Pathogens during Outbreaks of Infection,2013.0,"In the fall of 2011, by monitoring the increase in the number of combination cold medications (active ingredients: salicylamide, acetaminophen, anhydrous caffeine, and promethazine methylene disalicylate) prescribed since 2009, the prescription surveillance system detected an increase in the number of patients with symptoms of upper respiratory tract infections",,True,False,0,0,0,0.0,prescribed
14344,15463,a52d21e5ede2279aa09dbdaf2519391e795f6edd,acetaminophen,body,10.1016/b978-0-443-06981-9.50016-8,Chapter 11 Blood Donation and Collection,2007.0,"Hematomas, bruising, and soreness can usually be treated with compresses and acetaminophen",may,True,False,0,0,0,0.0,treated
14349,15468,a55cb4e724091ced46b5e55b982a14525eea1c7e,acetaminophen,body,10.1016/0002-9343(92)90608-e,Acute bronchitis: Results of U.S. and European trials of antibiotic therapy,1992.0,Patients with acute bronchitis that is suspected to be of viral origin are often treated with acetaminophen [4] and cough suppressants [3] for symptomatic relief,,True,False,0,0,0,0.0,treated
14456,15580,a646c8ced739fd583e7e031a90e4936f2a764035,acetaminophen,body,10.1371/journal.pone.0045027,Dynamics of a Cytokine Storm,2012.0,"These drugs -corticosteroids, chlorpheniramine, acetaminophen, ondansetron, metaraminol, methylprednisolene, and the anti-IL2 receptor antagonist antibody -could be administered safely to healthy subjects at low dosages for short periods of time",could,False,False,0,0,0,0.0,administer
14459,15583,a646c8ced739fd583e7e031a90e4936f2a764035,acetaminophen,body,10.1371/journal.pone.0045027,Dynamics of a Cytokine Storm,2012.0,"When the patients began to experience adverse side effects, clinicians treated the subjects with corticosteroids, chlorpheniramine, acetaminophen, ondansetron, metaraminol, methylprednisolene, and an anti-IL2 receptor antagonist antibody",,False,False,0,0,0,0.0,treated
14497,15625,a6ad42524cf9bc4815fe85f06ac6d87680ca179a,acetaminophen,body,10.1016/b978-012373960-5.00610-9,Rhinoviruses,2008.0,Mild fever may be treated with acetaminophen for few days.,potential,True,False,0,0,0,0.0,treated
14502,15630,a6b01a877ddbef5ae55335d3670b9654bbb594cc,cyclophosphamide,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"(c) Testosterone's suppression of focal infiltrate area, number of inflammatory cell foci, and percentage lymphocyte infiltration in lacrimal tissue may be duplicated by therapy with 19-nortestosterone and cyclophosphamide, but not by treatment with estradiol, danazol, cyclosporine A, or dexamethasone.",may,True,False,1,1,0,0.0,therapy
14503,15631,a6b01a877ddbef5ae55335d3670b9654bbb594cc,cyclophosphamide,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"(c) Testosterone's suppression of focal infiltrate area, number of inflammatory cell foci, and percentage lymphocyte infiltration in lacrimal tissue may be duplicated by therapy with 19-nortestosterone and cyclophosphamide, but not by treatment with estradiol, danazol, cyclosporine A, or dexamethasone.",may,True,False,1,1,0,0.0,therapy
14504,15632,a6b01a877ddbef5ae55335d3670b9654bbb594cc,cyclosporine,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"(c) Testosterone's suppression of focal infiltrate area, number of inflammatory cell foci, and percentage lymphocyte infiltration in lacrimal tissue may be duplicated by therapy with 19-nortestosterone and cyclophosphamide, but not by treatment with estradiol, danazol, cyclosporine A, or dexamethasone.",may,True,False,1,1,0,1.0,treatment
14505,15633,a6b01a877ddbef5ae55335d3670b9654bbb594cc,cyclosporine,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"(c) Testosterone's suppression of focal infiltrate area, number of inflammatory cell foci, and percentage lymphocyte infiltration in lacrimal tissue may be duplicated by therapy with 19-nortestosterone and cyclophosphamide, but not by treatment with estradiol, danazol, cyclosporine A, or dexamethasone.",may,True,False,1,1,0,1.0,treatment
14506,15634,a6b01a877ddbef5ae55335d3670b9654bbb594cc,danazol,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"(c) Testosterone's suppression of focal infiltrate area, number of inflammatory cell foci, and percentage lymphocyte infiltration in lacrimal tissue may be duplicated by therapy with 19-nortestosterone and cyclophosphamide, but not by treatment with estradiol, danazol, cyclosporine A, or dexamethasone.",may,True,False,1,1,0,1.0,treatment
14507,15635,a6b01a877ddbef5ae55335d3670b9654bbb594cc,danazol,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"(c) Testosterone's suppression of focal infiltrate area, number of inflammatory cell foci, and percentage lymphocyte infiltration in lacrimal tissue may be duplicated by therapy with 19-nortestosterone and cyclophosphamide, but not by treatment with estradiol, danazol, cyclosporine A, or dexamethasone.",may,True,False,1,1,0,1.0,treatment
14508,15636,a6b01a877ddbef5ae55335d3670b9654bbb594cc,dexamethasone,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"(c) Testosterone's suppression of focal infiltrate area, number of inflammatory cell foci, and percentage lymphocyte infiltration in lacrimal tissue may be duplicated by therapy with 19-nortestosterone and cyclophosphamide, but not by treatment with estradiol, danazol, cyclosporine A, or dexamethasone.",may,True,False,1,1,0,1.0,treatment
14509,15637,a6b01a877ddbef5ae55335d3670b9654bbb594cc,dexamethasone,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"(c) Testosterone's suppression of focal infiltrate area, number of inflammatory cell foci, and percentage lymphocyte infiltration in lacrimal tissue may be duplicated by therapy with 19-nortestosterone and cyclophosphamide, but not by treatment with estradiol, danazol, cyclosporine A, or dexamethasone.",may,True,False,1,1,0,1.0,treatment
14510,15638,a6b01a877ddbef5ae55335d3670b9654bbb594cc,estradiol,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"(c) Testosterone's suppression of focal infiltrate area, number of inflammatory cell foci, and percentage lymphocyte infiltration in lacrimal tissue may be duplicated by therapy with 19-nortestosterone and cyclophosphamide, but not by treatment with estradiol, danazol, cyclosporine A, or dexamethasone.",may,True,False,1,1,0,1.0,treatment
14511,15639,a6b01a877ddbef5ae55335d3670b9654bbb594cc,estradiol,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"(c) Testosterone's suppression of focal infiltrate area, number of inflammatory cell foci, and percentage lymphocyte infiltration in lacrimal tissue may be duplicated by therapy with 19-nortestosterone and cyclophosphamide, but not by treatment with estradiol, danazol, cyclosporine A, or dexamethasone.",may,True,False,1,1,0,1.0,treatment
14512,15640,a6b01a877ddbef5ae55335d3670b9654bbb594cc,testosterone,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,"These strategies, which are based upon the recognition that the endocrine, neural, and immune systems interact through extensive, regulatory pathways (90, 98-1011, are: (a) Administration of testosterone analogues with attenuated virilizing properties may directly suppress lacrimal gland immunopathology, thereby inhibiting immune-mediated destruction of acinar and ductal cells and alleviating the infiltrate-induced compression of glandular ducts",may,True,False,0,0,0,1.0,administration
14513,15641,a6b01a877ddbef5ae55335d3670b9654bbb594cc,testosterone,body,10.1016/0090-1229(92)90052-p,Potential therapeutic approach for the hormonal treatment of lacrimal gland dysfunction in SjÃ¶gren's syndrome,1992.0,These murine investigations have demonstrated that: (a) Testosterone therapy induces a precipitous decrease in the extent of lymphocyte infiltration in lacrimal tissue,may,True,False,0,0,0,1.0,therapy
14530,15666,a7141750bb01c98352bde01baff3156331b41c9b,acetate,body,10.1016/b978-1-4377-0660-4.00040-5,Chapter 40 Female Reproduction,2012.0,"Megestrol acetate (Ovaban, Intervet/ Schering-Plough Animal Health [Summit, NJ] and others) is effective for suppressing estrus in queens when given orally, starting in anestrus (2.5 to 5 mg/cat once daily for 5 days, then once weekly)",,True,False,0,0,0,0.0,effective
14678,15826,a92f695c75e4349fd76931c1800bb722ac5eca0b,acetaminophen,body,10.1016/b978-0-12-819400-3.00016-8,Chapter 16 Dengue Virus,2020.0,"Potential mechanisms for hepatic injury involve a variety of possible insults, including direct effects of the virus or host immune response on liver cells, circulatory compromise, and/or hypoxia due to hypotension or localized vascular leakage inside the liver capsule, hepatotoxic effects of drugs such as acetaminophen or traditional herbal remedies, and tissue tropism of particular viral serotypes or genotypes.",,False,False,0,0,0,1.0,effect
14717,15872,aa1eaad52d7a7827850cecf3d6b582e728e7e543,acetate,body,10.1186/1751-0147-55-67,Haemorrhagic pneumonia in sled dogs caused by Streptococcus equi subsp. zooepidemicus - one fatality and two full recoveries: a case report,2013.0,"The dog was treated with intravenous (IV) ringer acetate 100 ml/kg/hr for eight hours, thereafter 50 ml/kg/hr, enrofloxacin (Baytril, vet",,True,True,0,0,0,0.0,treated
14735,15890,aa36e8d21c62925bbaa87429a45a81d0ef78b154,acetate,body,10.1016/j.amjoto.2007.11.004,Safety of intranasal corticosteroids in acute rhinosinusitis,2008.0,"A 1993 parallel-group study found evidence of suppressed short-term lower-leg growth, as measured by knemometry, with BUD (200 Î¼g BID) or intramuscular methylprednisolone acetate (60 mg QD) when compared to terfenadine tablets (60 mg QD) in 44 children (aged 6-15 years) with AR",,True,False,0,0,0,1.0,suppress
14975,16150,ae8299ba334c3f5aa2b008f8862b6243c6eeb42e,acetaminophen,body,10.1016/b978-1-4377-0660-4.00025-9,Chapter 25 Hematology and Immune-Related Disorders,2012.0,N-acetylcysteine is used to treat acetaminophen toxicity (see Chapter 31) ,may,True,True,0,0,0,1.0,treat
14983,16159,ae8299ba334c3f5aa2b008f8862b6243c6eeb42e,acetaminophen,body,10.1016/b978-1-4377-0660-4.00025-9,Chapter 25 Hematology and Immune-Related Disorders,2012.0,Owners sometimes unwittingly administer acetaminophen to cats that seem to be in pain.,may,True,True,0,0,0,0.0,administer
15300,16498,b30770ae30b35cdfaf0a173863e74e93edbb0329,norepinephrine,body,10.1186/s13054-016-1208-6,"36th International Symposium on Intensive Care and Emergency Medicine: Brussels, Belgium. 15-18 March 2016",2016.0,[1] We hypothesized that a dose of norepinephrine administered in the first 24 hours correlates with the outcome of treatment in patients with severe sepsis and septic shock,,True,True,0,0,0,0.0,administered
15361,16565,b420e61b7bad7118736507f69d3a255d5d171dea,acetaminophen,body,,,,Flu-like symptoms can be treated with acetaminophen 500-1000 mg or ibuprofen 200-400 mg 30 minutes before IFN Î²-1a injection.,,False,False,0,0,0,0.0,treated
15595,16816,b6b5c3ce6a1295e172b7e8406dae5a453b031b88,acetaminophen,body,10.1016/j.jtbi.2011.08.009,In vitro transcriptomic prediction of hepatotoxicity for early drug discovery,2011.0,"In these two studies, commonly-used drug compounds, Acetaminophen (Rat2) and 1,4-dichlorobenzene (Rat3) respectively, were administered for 6, 24, or 48 consecutive hrs at different dose concentrations to evaluate the levels of acute toxicity of in vivo animals",,False,False,0,0,0,1.0,administer
16159,17429,bbff324ce85ca876d0c96244b3c9fa479c7f300f,acetate,abstract,10.3324/haematol.2010.027821,Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance,2010.0,"Our data indicate the potential of bezafibrate, medroxyprogesterone acetate and lycorine as novel therapy in chronic lymphocytic leukemia and have important implications for the reported potential of c-abl kinase inhibitors in this disease.",,False,False,0,0,0,0.0,therapy
16167,17437,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,ranolazine,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"CV Therapeutics, under license from Roche, is also developing ranolazine, a metabolic modulator and a partial fatty acid oxidation inhibitor, for the potential treatment of angina and acute coronary syndromes",potential,False,False,0,0,0,0.0,Therapeutics
16169,17439,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,ambisome,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"Gilead has several antiinfectious products on the market: * Emtricitabine, a nucleoside analog licensed from Emory University that is structurally related to 3TC for the treatment of HIV infection * Cidofovir, a specific nucleotide inhibitor of viral replication, which was launched in an injectable formulation in 1996 * Oseltamivir (Tamiflu: 5), a neuraminidase inhibitor, for the treatment and prevention of influenza virus type A or B infections * Tenofovir disoproxil fumarate (6), an oral prodrug of the intravenously administered antiviral agent tenofovir used for the treatment and prophylaxis of HIV infection * AmBisome, a liposomal formulation of amphotericin B, jointly developed by NeXstar and Lyphomed, marketed for systemic fungal infections and in the US for cancer and acquired immunodeficiency syndrome (AIDS) patients with blood-borne fungal infections * Adefovir dipivoxil, an analog of the reverse transcriptase inhibitor adefovir for the treatment of HBV infection",,False,False,0,0,0,0.0,treatment
16170,17440,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,cidofovir,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"Gilead has several antiinfectious products on the market: * Emtricitabine, a nucleoside analog licensed from Emory University that is structurally related to 3TC for the treatment of HIV infection * Cidofovir, a specific nucleotide inhibitor of viral replication, which was launched in an injectable formulation in 1996 * Oseltamivir (Tamiflu: 5), a neuraminidase inhibitor, for the treatment and prevention of influenza virus type A or B infections * Tenofovir disoproxil fumarate (6), an oral prodrug of the intravenously administered antiviral agent tenofovir used for the treatment and prophylaxis of HIV infection * AmBisome, a liposomal formulation of amphotericin B, jointly developed by NeXstar and Lyphomed, marketed for systemic fungal infections and in the US for cancer and acquired immunodeficiency syndrome (AIDS) patients with blood-borne fungal infections * Adefovir dipivoxil, an analog of the reverse transcriptase inhibitor adefovir for the treatment of HBV infection",,False,False,0,0,0,0.0,treatment
16171,17441,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,emtricitabine,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"Gilead has several antiinfectious products on the market: * Emtricitabine, a nucleoside analog licensed from Emory University that is structurally related to 3TC for the treatment of HIV infection * Cidofovir, a specific nucleotide inhibitor of viral replication, which was launched in an injectable formulation in 1996 * Oseltamivir (Tamiflu: 5), a neuraminidase inhibitor, for the treatment and prevention of influenza virus type A or B infections * Tenofovir disoproxil fumarate (6), an oral prodrug of the intravenously administered antiviral agent tenofovir used for the treatment and prophylaxis of HIV infection * AmBisome, a liposomal formulation of amphotericin B, jointly developed by NeXstar and Lyphomed, marketed for systemic fungal infections and in the US for cancer and acquired immunodeficiency syndrome (AIDS) patients with blood-borne fungal infections * Adefovir dipivoxil, an analog of the reverse transcriptase inhibitor adefovir for the treatment of HBV infection",,False,False,0,0,0,0.0,treatment
16172,17442,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,oseltamivir,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"Gilead has several antiinfectious products on the market: * Emtricitabine, a nucleoside analog licensed from Emory University that is structurally related to 3TC for the treatment of HIV infection * Cidofovir, a specific nucleotide inhibitor of viral replication, which was launched in an injectable formulation in 1996 * Oseltamivir (Tamiflu: 5), a neuraminidase inhibitor, for the treatment and prevention of influenza virus type A or B infections * Tenofovir disoproxil fumarate (6), an oral prodrug of the intravenously administered antiviral agent tenofovir used for the treatment and prophylaxis of HIV infection * AmBisome, a liposomal formulation of amphotericin B, jointly developed by NeXstar and Lyphomed, marketed for systemic fungal infections and in the US for cancer and acquired immunodeficiency syndrome (AIDS) patients with blood-borne fungal infections * Adefovir dipivoxil, an analog of the reverse transcriptase inhibitor adefovir for the treatment of HBV infection",,False,False,0,0,0,0.0,treatment
16173,17443,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,tenofovir,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"Gilead has several antiinfectious products on the market: * Emtricitabine, a nucleoside analog licensed from Emory University that is structurally related to 3TC for the treatment of HIV infection * Cidofovir, a specific nucleotide inhibitor of viral replication, which was launched in an injectable formulation in 1996 * Oseltamivir (Tamiflu: 5), a neuraminidase inhibitor, for the treatment and prevention of influenza virus type A or B infections * Tenofovir disoproxil fumarate (6), an oral prodrug of the intravenously administered antiviral agent tenofovir used for the treatment and prophylaxis of HIV infection * AmBisome, a liposomal formulation of amphotericin B, jointly developed by NeXstar and Lyphomed, marketed for systemic fungal infections and in the US for cancer and acquired immunodeficiency syndrome (AIDS) patients with blood-borne fungal infections * Adefovir dipivoxil, an analog of the reverse transcriptase inhibitor adefovir for the treatment of HBV infection",,False,False,0,0,0,0.0,treatment
16174,17444,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,actimmune,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16175,17445,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,actimmune,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16176,17446,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,actimmune,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16177,17447,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,alteplase,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16178,17448,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,alteplase,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16179,17449,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,alteplase,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16180,17450,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,bevacizumab,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,therapy
16181,17451,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,bevacizumab,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,therapy
16182,17452,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,bevacizumab,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,therapy
16183,17453,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,erlotinib,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16184,17454,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,erlotinib,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16185,17455,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,erlotinib,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16186,17456,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,kogenate,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treating
16187,17457,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,kogenate,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treating
16188,17458,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,kogenate,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treating
16189,17459,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,omalizumab,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16190,17460,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,omalizumab,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16191,17461,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,omalizumab,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16192,17462,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,tenecteplase,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16193,17463,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,tenecteplase,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16194,17464,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,tenecteplase,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16195,17465,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,trastuzumab,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16196,17466,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,trastuzumab,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16197,17467,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,trastuzumab,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"19 These are * Actimmune (IFN-g1b), launched for the treatment of infections in patients with chronic granulomatous disease * Alteplase (recombinant tissue plasminogen activator, marketed in the US in 1987 for the treatment of acute myocardial infarction, in 1990 for use in the treatment of acute pulmonary embolism, and in June 1996 for the treatment of acute ischemic stroke within 3 h of symptom onset) * Bevacizumab (intravenously administered antivascular endothelial growth factor monoclonal antibody), an antiangiogenesis therapy for the treatment of colorectal cancer * Dornase alfa, a DNase which has been developed and launched for the treatment of cystic fibrosis * Efalizumab, a humanized anti-CD11a monoclonal antibody as a once-weekly subcutaneous formulation, for the treatment of moderate-to-severe plaque psoriasis * Kogenate, a recombinant human factor VIII preparation used for treating hemophiliacs * Omalizumab, an anti-IgE humanized monoclonal antibody for the treatment of asthma * Recombinant somatotropin, first launched in 1987 for the treatment of growth hormone deficiency in children, children with chronic renal insufficiency, and children with short stature associated with Turner's syndrome * Tenecteplase, an injectable, slower-clearing, fibrin-specific tissue plasminogen activator for the treatment of myocardial infarction, first launched in the US in June 2000 and in 2001 in the EU * Trastuzumab, a humanized version of the anti-HER-2/neu monoclonal antibody, 4D5, and marketed for the treatment of metastatic breast cancer since 1998 * Roferon-A, a recombinant interferon-a 2a that has been developed and used for the treatment of various lymphomas, leukemias, and other neoplasms, and for the treatment of chronic hepatitis B and C virus (HBV and HCV) infections * Ituximab, a mouse/human chimeric anti-CD20 monoclonal antibody, used for the treatment of B-cell nonHodgkin's lymphoma, including relapsed, refractory low-grade, or follicular lymphomas The Role of Small-or Medium-Sized Enterprises in Drug Discovery * Erlotinib (1), a small-molecule, orally active epidermal growth factor receptor tyrosine kinase inhibitor (discovered by but relinquished by Pfizer after the merger with Warner-Lambert), for the treatment of nonsmall-cell lung cancer.",,False,False,0,0,0,0.0,treatment
16201,17471,bc2e4e1d49b8faa6fbff4449fdb7961f12eb023d,acetylcholine,body,10.1016/b0-08-045044-x/00016-x,1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery,2007.0,"Targacept is researching novel approaches to treat pain, including a 4 b 2 neuronal nicotinic acetylcholine receptors that are known to have pain-relieving effects in animals.",,False,False,0,0,0,0.0,effect
16234,17513,bcfa3dbb3fadcb51bd684e07b654328d2bf4e0db,acetate,body,10.1186/1746-6148-9-21,Continuous intravenous anaesthesia with sufentanil and midazolam in medetomidine premedicated New Zealand White rabbits,2013.0,"Warmed Ringer acetate solution (Fresenius Kabi, Sweden) was administered IV at a rate of 20 mL/kg BW/h.",,True,False,0,0,0,0.0,administer
16353,17642,be7e8df88e63d2579e8d61e2c3d716d57d347676,acetate,body,10.1016/b978-0-7020-5318-4.00011-5,Chapter 5 Respiratory System,2016.0,"Epidemiologic evidence suggests 3-methylindole, melengestrol acetate (fed to feedlot heifers to suppress estrus), high-energy diets, dusty environment, hot weather, and concurrent bacterial infection as possible causes or contributing factors",,True,True,0,0,0,1.0,suppress
16448,17745,c0afcaab27d3532f3396316eb529468097bd6de7,abatacept,body,10.3389/fimmu.2017.00157,TNF Blockade Maintains an IL-10(+) Phenotype in Human Effector CD4(+) and CD8(+) T Cells,2017.0,"Addition of tocilizumab (IL-6R blockade) or abatacept (CTLA4-Ig, which blocks CD80/CD86-mediated co-stimulation), both of which are biologic drugs routinely used in the clinic to treat rheumatoid arthritis, did not increase IL-10 + frequencies in CD4 + T cells, IL-17 + , IFNÎ³ + , or TNFÎ± + CD4 + T cell subpopulations (Figure 4B) ",could,True,True,1,1,0,0.0,treat
16886,18214,c654596857bce9cdd64ffc51842048643107348c,acetaminophen,body,10.1016/s0924-8579(02)00033-x,ECC-4 Abstracts,2002.0,"Antibiotics were administered subcutaneously 2 h post-middle ear inoculation, and continued t.i.d for 24 h, with or without acetaminophen (AP), at 50 mg/kg, administered 30 min before each antibiotic dose",,False,False,1,1,0,0.0,administered
16890,18218,c654596857bce9cdd64ffc51842048643107348c,acetate,body,10.1016/s0924-8579(02)00033-x,ECC-4 Abstracts,2002.0,"We treated 27 MSF patients with doxycycline 2)/100 mg/day, 25 patients with clarithromycin 2)/250 mg/day, as well as 25 patients with midecamycin 2)/400 mg/day and midecamycin acetate 30 mg/kg/day",,False,False,0,0,0,0.0,treated
16998,18336,c7f8760df509ef0c7f11a4c1bc9851f15b07fd78,copaxone,body,10.1016/s0074-7742(07)79003-7,The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis,2007.0,Glatiramer acetate (GA; Copolymer-1; Copaxone ) is an FDA approved therapy for the treatment of RRMS,,True,False,0,0,0,0.0,therapy
17098,18441,c92979742ed6e66042352106864dd89d106fb2dc,acetylcholine,body,10.1097/mol.0000000000000340,DPP4 Inhibition: Insights From the Bench and Recent Clinical Studies,2016.0,"Treatment with vildagliptin for 4 weeks in patients with type 2 diabetes improved forearm blood vasodilator responses to intra-arterially administered acetylcholine, but not to sodium nitroprusside [30] ",may,False,False,1,1,0,0.0,administered
17113,18457,c93491cabf0aa17c8ba1f05e01701e6bfe7a4fd1,propecia,body,10.1016/b0-08-045044-x/00025-0,1.22 Bioethical Issues in Medicinal Chemistry and Drug Treatment,2007.0,"115 In the wake of consumer demand, pharmaceutical companies have increasingly begun to focus on lucrative life style drugs, such as remedies for impotence (Pfizer's Viagra), baldness (Merck's Propecia), weight reduction (Abbott's Meridia), and facial wrinkles (Allergan's Botox)",potential,False,False,0,0,0,0.0,remedies
17116,18460,c93491cabf0aa17c8ba1f05e01701e6bfe7a4fd1,viagra,body,10.1016/b0-08-045044-x/00025-0,1.22 Bioethical Issues in Medicinal Chemistry and Drug Treatment,2007.0,"115 In the wake of consumer demand, pharmaceutical companies have increasingly begun to focus on lucrative life style drugs, such as remedies for impotence (Pfizer's Viagra), baldness (Merck's Propecia), weight reduction (Abbott's Meridia), and facial wrinkles (Allergan's Botox)",potential,False,False,0,0,0,0.0,remedies
17234,18590,cabe6a81b684ef3c7b8febdc093f1aacbe06ced6,testosterone,body,10.3389/fimmu.2018.01547,Advancements in Host-Based Interventions for Influenza Treatment,2018.0,"Type I IFNs, prostaglandin I2, corticosteroids, and testosterone have been reported to suppress ILC2 activity (172, 173) ",,True,True,0,0,0,0.0,suppress
17288,18647,cbfddc279c85195d10ea9034eb7a599edd458693,ribavirin,body,10.1016/j.antiviral.2006.01.006,Treatment of respiratory virus infections,2006.0,(2004) also evaluated lopinavir/ritonavir treatment compared with historic controls; all patients were also treated with ribavirin and steroids,could,True,True,0,0,0,0.0,treated
17485,18863,ceb8a6b92ffbe82a86442218bdff2b8a11a4dbe4,acetate,body,10.1016/b978-0-7020-5246-0.00012-7,12 Diseases of the Respiratory System,2017.0,"Melengestrol acetate (MGA), a feed additive commonly fed to feedlot heifers to suppress estrus, has been associated with AIP based on epidemiologic evidence",,True,True,0,0,0,1.0,suppress
17707,19097,cfe62b4ea5e08692abe18bdf297dc527dfa5345f,amiloride,body,10.1533/9781908818195.1,1 Nanoparticulate systems as drug carriers: the need,2012.0,"In this book, we intend to provide an overview of these different therapeutic nanoparticles, the challenges Examples of nanoparticulate carriers targeted to the lung (modifi ed from [107] [108] [109] Amphotericin B Phospholipid and apolipoprotein Lung infection [114] Amiloride hydrochloride Liposome Cystic fi brosis [108] Secretory leukocyte protease inhibitor Liposome Cystic fi brosis [115] Interleukin-4 antisense oligodeoxynucleotides Polymeric nanoparticle Asthma [116] Vasoactive intestinal peptide Protamine nanoparticle Asthma [117] Indomethacin, ketoprofen Solid Lipid nanoparticles Asthma [108] Antisense oligonucleotide 2'-O-methyl-RNA PLGA nanoparticles Lung cancer [118] Leuprolide Liposome Lung cancer [108] HLA-A*0201-restricted T-cell epitopes from Mycobacterium tuberculosis Chitosan nanoparticles Tuberculosis [119] V1Jns plasmid encoding antigen 85B from M",may,False,False,0,0,0,0.0,therapeutic
17708,19098,cfe62b4ea5e08692abe18bdf297dc527dfa5345f,indomethacin,body,10.1533/9781908818195.1,1 Nanoparticulate systems as drug carriers: the need,2012.0,"In this book, we intend to provide an overview of these different therapeutic nanoparticles, the challenges Examples of nanoparticulate carriers targeted to the lung (modifi ed from [107] [108] [109] Amphotericin B Phospholipid and apolipoprotein Lung infection [114] Amiloride hydrochloride Liposome Cystic fi brosis [108] Secretory leukocyte protease inhibitor Liposome Cystic fi brosis [115] Interleukin-4 antisense oligodeoxynucleotides Polymeric nanoparticle Asthma [116] Vasoactive intestinal peptide Protamine nanoparticle Asthma [117] Indomethacin, ketoprofen Solid Lipid nanoparticles Asthma [108] Antisense oligonucleotide 2'-O-methyl-RNA PLGA nanoparticles Lung cancer [118] Leuprolide Liposome Lung cancer [108] HLA-A*0201-restricted T-cell epitopes from Mycobacterium tuberculosis Chitosan nanoparticles Tuberculosis [119] V1Jns plasmid encoding antigen 85B from M",may,False,False,0,0,0,0.0,therapeutic
17709,19099,cfe62b4ea5e08692abe18bdf297dc527dfa5345f,ketoprofen,body,10.1533/9781908818195.1,1 Nanoparticulate systems as drug carriers: the need,2012.0,"In this book, we intend to provide an overview of these different therapeutic nanoparticles, the challenges Examples of nanoparticulate carriers targeted to the lung (modifi ed from [107] [108] [109] Amphotericin B Phospholipid and apolipoprotein Lung infection [114] Amiloride hydrochloride Liposome Cystic fi brosis [108] Secretory leukocyte protease inhibitor Liposome Cystic fi brosis [115] Interleukin-4 antisense oligodeoxynucleotides Polymeric nanoparticle Asthma [116] Vasoactive intestinal peptide Protamine nanoparticle Asthma [117] Indomethacin, ketoprofen Solid Lipid nanoparticles Asthma [108] Antisense oligonucleotide 2'-O-methyl-RNA PLGA nanoparticles Lung cancer [118] Leuprolide Liposome Lung cancer [108] HLA-A*0201-restricted T-cell epitopes from Mycobacterium tuberculosis Chitosan nanoparticles Tuberculosis [119] V1Jns plasmid encoding antigen 85B from M",may,False,False,0,0,0,0.0,therapeutic
17710,19100,cfe62b4ea5e08692abe18bdf297dc527dfa5345f,leuprolide,body,10.1533/9781908818195.1,1 Nanoparticulate systems as drug carriers: the need,2012.0,"In this book, we intend to provide an overview of these different therapeutic nanoparticles, the challenges Examples of nanoparticulate carriers targeted to the lung (modifi ed from [107] [108] [109] Amphotericin B Phospholipid and apolipoprotein Lung infection [114] Amiloride hydrochloride Liposome Cystic fi brosis [108] Secretory leukocyte protease inhibitor Liposome Cystic fi brosis [115] Interleukin-4 antisense oligodeoxynucleotides Polymeric nanoparticle Asthma [116] Vasoactive intestinal peptide Protamine nanoparticle Asthma [117] Indomethacin, ketoprofen Solid Lipid nanoparticles Asthma [108] Antisense oligonucleotide 2'-O-methyl-RNA PLGA nanoparticles Lung cancer [118] Leuprolide Liposome Lung cancer [108] HLA-A*0201-restricted T-cell epitopes from Mycobacterium tuberculosis Chitosan nanoparticles Tuberculosis [119] V1Jns plasmid encoding antigen 85B from M",may,False,False,0,0,0,0.0,therapeutic
17711,19101,cfe62b4ea5e08692abe18bdf297dc527dfa5345f,protamine,body,10.1533/9781908818195.1,1 Nanoparticulate systems as drug carriers: the need,2012.0,"In this book, we intend to provide an overview of these different therapeutic nanoparticles, the challenges Examples of nanoparticulate carriers targeted to the lung (modifi ed from [107] [108] [109] Amphotericin B Phospholipid and apolipoprotein Lung infection [114] Amiloride hydrochloride Liposome Cystic fi brosis [108] Secretory leukocyte protease inhibitor Liposome Cystic fi brosis [115] Interleukin-4 antisense oligodeoxynucleotides Polymeric nanoparticle Asthma [116] Vasoactive intestinal peptide Protamine nanoparticle Asthma [117] Indomethacin, ketoprofen Solid Lipid nanoparticles Asthma [108] Antisense oligonucleotide 2'-O-methyl-RNA PLGA nanoparticles Lung cancer [118] Leuprolide Liposome Lung cancer [108] HLA-A*0201-restricted T-cell epitopes from Mycobacterium tuberculosis Chitosan nanoparticles Tuberculosis [119] V1Jns plasmid encoding antigen 85B from M",may,False,False,0,0,0,0.0,therapeutic
17712,19102,cfe62b4ea5e08692abe18bdf297dc527dfa5345f,abraxane,body,10.1533/9781908818195.1,1 Nanoparticulate systems as drug carriers: the need,2012.0,Abraxane Â® is another commercially successful product for the targeted cancer therapy,,False,False,0,0,0,0.0,therapy
17845,19253,d127e9fa7bcad289c4435d88c3e779ec46dd6de0,acetate,body,10.1016/j.virusres.2007.09.009,Expression and biochemical characterization of nsP2 cysteine protease of Chikungunya virus,2008.0,"As zinc salts (zinc acetate) are already used as therapeutics in humans, they could represent a promising drug for treatment of other viral infections.",,True,True,0,0,0,0.0,therapeutics
18052,19470,d2b8c64e77ae824f20369bd17ccb3b5de5bd8bd5,acetaminophen,body,10.1016/s0091-6749(95)70218-0,The common cold: Current therapy and natural history,1995.0,Aspirin and acetaminophen suppress sero-neutralizing antibody response (p < 0.05) and are associated with increased nasal symptoms and signs,may,True,False,0,0,0,1.0,suppress
18102,19521,d3744e7581b12fe33a93e21e89b5da988b790b4b,acetaminophen,body,10.1016/s0011-5029(96)90012-7,Multiple sclerosis,1996.0,An antipyretic medication such as acetaminophen can then be administered,may,True,False,0,0,0,0.0,administered
18168,19592,d4dc23273969e82b991c849b9538455ffd4642a6,levofloxacin,body,10.1016/b978-0-323-29634-2.00001-8,1 Syndromal Tropical Dermatology,2017.0,"A number of agents taken to treat or prevent diarrhea can also cause cutaneous reactions, such as quinolones (ciprofloxacin, ofloxacin, sparfloxacin, levofloxacin), furazolidone, metronidazole, trimethoprim-sulfamethoxazole and bismuth sulfate; quinolones are particularly likely to produce photosensitivity",may,False,False,0,0,0,0.0,treat
18169,19593,d4dc23273969e82b991c849b9538455ffd4642a6,metronidazole,body,10.1016/b978-0-323-29634-2.00001-8,1 Syndromal Tropical Dermatology,2017.0,"A number of agents taken to treat or prevent diarrhea can also cause cutaneous reactions, such as quinolones (ciprofloxacin, ofloxacin, sparfloxacin, levofloxacin), furazolidone, metronidazole, trimethoprim-sulfamethoxazole and bismuth sulfate; quinolones are particularly likely to produce photosensitivity",may,False,False,0,0,0,1.0,treat
18170,19594,d4dc23273969e82b991c849b9538455ffd4642a6,trimethoprim,body,10.1016/b978-0-323-29634-2.00001-8,1 Syndromal Tropical Dermatology,2017.0,"A number of agents taken to treat or prevent diarrhea can also cause cutaneous reactions, such as quinolones (ciprofloxacin, ofloxacin, sparfloxacin, levofloxacin), furazolidone, metronidazole, trimethoprim-sulfamethoxazole and bismuth sulfate; quinolones are particularly likely to produce photosensitivity",may,False,False,0,0,0,1.0,treat
18171,19595,d4dc23273969e82b991c849b9538455ffd4642a6,lindane,body,10.1016/b978-0-323-29634-2.00001-8,1 Syndromal Tropical Dermatology,2017.0,"In contrast to many STDs, however, these ectoparasites can be easily treated with topical medications such as lindane or permethrin",,False,False,0,0,0,0.0,treated
18172,19596,d4dc23273969e82b991c849b9538455ffd4642a6,permethrin,body,10.1016/b978-0-323-29634-2.00001-8,1 Syndromal Tropical Dermatology,2017.0,"In contrast to many STDs, however, these ectoparasites can be easily treated with topical medications such as lindane or permethrin",,False,False,0,0,0,0.0,treated
18173,19597,d4dc23273969e82b991c849b9538455ffd4642a6,imiquimod,body,10.1016/b978-0-323-29634-2.00001-8,1 Syndromal Tropical Dermatology,2017.0,"Like condyloma acuminatum, however, MC can be treated with cytodestructive therapy, surgery, or imiquimod.",,False,False,0,0,0,0.0,treated
18174,19598,d4dc23273969e82b991c849b9538455ffd4642a6,imiquimod,body,10.1016/b978-0-323-29634-2.00001-8,1 Syndromal Tropical Dermatology,2017.0,"Like condyloma acuminatum, however, MC can be treated with cytodestructive therapy, surgery, or imiquimod.",,False,False,0,0,0,0.0,treated
18175,19599,d4dc23273969e82b991c849b9538455ffd4642a6,imiquimod,body,10.1016/b978-0-323-29634-2.00001-8,1 Syndromal Tropical Dermatology,2017.0,"Like condyloma acuminatum, however, MC can be treated with cytodestructive therapy, surgery, or imiquimod.",,False,False,0,0,0,0.0,treated
18176,19600,d4dc23273969e82b991c849b9538455ffd4642a6,imiquimod,body,10.1016/b978-0-323-29634-2.00001-8,1 Syndromal Tropical Dermatology,2017.0,"Like condyloma acuminatum, however, MC can be treated with cytodestructive therapy, surgery, or imiquimod.",,False,False,0,0,0,0.0,treated
18355,19793,d66ae5018881c39ecd2d5c8f741dfff0a77442f7,acetate,body,10.1016/j.virol.2008.02.021,Early growth response-1 protein is induced by JC virus infection and binds and regulates the JC virus promoter,2008.0,Cells were transfected with and without pCMV-Sp1 or pCMV-Egr-1 for 48 hours and then treated with 100 ng/ml tetradecanoyl phorbol acetate (TPA) for 90 min except for the experiment in Fig,,False,False,1,1,0,0.0,treated
18395,19840,d6a3bc04e0e9d2244f5d0409aae275bd4d68a3af,acetate,body,10.1016/b978-0-323-31696-5.00103-0,Chapter 103 Osteonecrosis,2017.0,"187 A group of researchers studied the use of adrenocorticotropic hormone (ACTH) in rabbits to prevent corticosteroid-induced osteonecrosis and found that if ACTH is administered along with depot methylprednisolone acetate (Depo-Medrol), osteonecrosis is reduced",may,True,False,0,0,0,0.0,administered
18425,19872,d7553682c41c12e43ac32cf2715fbf8c64026a1b,ciprofloxacin,body,10.1016/j.tmaid.2019.07.006,"â€œHealthy Hajj 2019â€ â€“â€“ what you need to know, before you go",2019.0,"[4, 5] In addition, decolonization of N meningitidis with a single dose of ciprofloxacin will be administered at the ports of entry for pilgrims coming from the African meningitis belt",,False,False,0,0,0,0.0,administered
18469,19921,d7c6dce06425c809941d8c8588521c8bb968c902,acetazolamide,body,10.1016/b978-1-4557-0892-5.00031-3,Chapter 31 Neonatology,2014.0,â€¢ Severe cases need to be managed with acetazolamide (2 mg/kg PO q12h) and/or phenytoin (2.8 to 10 mg/kg PO q12h),,False,False,0,0,0,0.0,managed
18479,19931,d7fb96e8ec2ba7cf7ad3d74159f9cec09b1ae4e7,acetate,body,10.1016/j.cvfa.2010.04.001,Pathogenesis and Pathology of Bovine Pneumonia,2010.0,54 Interstitial pneumonia also was described with some frequency in feedlot heifers fed melengestrol acetate to suppress estrus,potential,True,True,0,0,0,1.0,suppress
18501,19956,d89a1a60a3873bbcf68b3ec0ffcb1fc3cb276205,acetate,body,10.1016/j.jneuroim.2006.07.002,ISNI 2006 Abstracts,2006.0,"Antibody independent clearance of A-beta in a mouse model of Alzheimer's disease by activation of microglia via nasal vaccination Methods: Age-and sex-matched littermates (APP-J20 mice) received a weekly nasal treatment with Protollin (a proteosome-based adjuvant used in human influenza vaccination) 1 Î¼g/treatment, plus glatiramer acetate (GA, an approved drug for MS) 25 Î¼g/treatment, beginning at age 5 months and were treated for 8 months",,True,False,0,0,0,0.0,treatment
18502,19957,d89a1a60a3873bbcf68b3ec0ffcb1fc3cb276205,glatiramer,body,10.1016/j.jneuroim.2006.07.002,ISNI 2006 Abstracts,2006.0,"Antibody independent clearance of A-beta in a mouse model of Alzheimer's disease by activation of microglia via nasal vaccination Methods: Age-and sex-matched littermates (APP-J20 mice) received a weekly nasal treatment with Protollin (a proteosome-based adjuvant used in human influenza vaccination) 1 Î¼g/treatment, plus glatiramer acetate (GA, an approved drug for MS) 25 Î¼g/treatment, beginning at age 5 months and were treated for 8 months",,True,False,0,0,0,0.0,treatment
18513,19968,d89a1a60a3873bbcf68b3ec0ffcb1fc3cb276205,acetate,body,10.1016/j.jneuroim.2006.07.002,ISNI 2006 Abstracts,2006.0,"Glatiramer acetate (Copaxone) therapy restores regulatory, cytotoxic, HLA-E-restricted CD8 + T cells in multiple sclerosis One of the goals of successful therapeutic immune modulation of autoimmune disease is the induction of peripheral tolerance, a large part of which is mediated by regulatory/suppressor T cells",,True,False,0,0,0,0.0,therapy
18514,19969,d89a1a60a3873bbcf68b3ec0ffcb1fc3cb276205,acetate,body,10.1016/j.jneuroim.2006.07.002,ISNI 2006 Abstracts,2006.0,"Glatiramer acetate (Copaxone) therapy restores regulatory, cytotoxic, HLA-E-restricted CD8 + T cells in multiple sclerosis One of the goals of successful therapeutic immune modulation of autoimmune disease is the induction of peripheral tolerance, a large part of which is mediated by regulatory/suppressor T cells",,True,False,0,0,0,0.0,therapy
18515,19970,d89a1a60a3873bbcf68b3ec0ffcb1fc3cb276205,acetate,body,10.1016/j.jneuroim.2006.07.002,ISNI 2006 Abstracts,2006.0,Glatiramer acetate mediated immune modulation is driven by antigen presenting cells and is not T cell antigen specific Background: GA exerts therapeutic benefit in multiple sclerosis presumably by induction of GA-specific Th2-cells,,True,False,1,1,0,0.0,therapeutic
18603,20061,d9bc72dcb21981faa5504ca0b2d670013d61dfdf,acetaminophen,body,10.1016/j.annemergmed.2006.11.014,"Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute Goutlike Arthritis: A Double-Blind, Randomized, Controlled Trial",2007.0,"8 According to the findings in our study, we recommend that moderate doses of oral prednisolone supplemented with oral acetaminophen be considered as first-line therapy in the treatment of acute gout.",possible,False,False,0,0,0,0.0,therapy
18706,20173,db139f1bc96dc1b72ab2ec3b3eaff1510a1e9368,metronidazole,body,10.1007/s12223-019-00759-3,"Probiotics and prebiotics potential for the care of skin, female urogenital tract, and respiratory tract",2019.0,(2014) compared the efficacy of vaginally administered probiotic vaginal tampons with oral metronidazole for the treatment of BV,,True,False,0,0,0,0.0,treatment
18719,20186,db25c69d8c4a481f4bf3da197dd20414cd245fa5,acetaminophen,body,10.1093/bja/aep375,Pandemic (H1N1) 2009 influenza,2010.0,Fever during pregnancy should be treated with acetaminophen due to the risk to the fetus,possible,False,False,0,0,0,0.0,treated
18786,20255,dc2451c2166ef31db7fc2ad93ade6bf4d18c55e2,acetate,body,10.3390/md12042114,Insights and Ideas Garnered from Marine Metabolites for Development of Dual-Function Acetylcholinesterase and Amyloid-Î² Aggregation Inhibitors,2014.0,"Determination of cholinesterase isozyme specificity (AChE versus butrylcholinesterase) and effects on amyloid-Î² aggregation for the sesquiterpene acetate [21, 22] , pyrrole derivative, PZT-compound, plastoquinones, and farnesylacetones classes of MM described in this article would provide an additional guide to development of novel compounds as therapies for Alzheimer's disease.",may,False,False,0,0,0,0.0,effects
18801,20271,dc2f210539245c7a03dcaa21c9305555d10ece43,acetate,body,10.1016/j.clim.2005.03.007,FOCIS abstract supplement,2005.0,non-responders to betainterferon or glatiramer acetate therapy (n = 38 vs,,True,True,0,0,0,0.0,therapy
18802,20272,dc2f210539245c7a03dcaa21c9305555d10ece43,glatiramer,body,10.1016/j.clim.2005.03.007,FOCIS abstract supplement,2005.0,non-responders to betainterferon or glatiramer acetate therapy (n = 38 vs,,True,True,0,0,0,0.0,therapy
18837,20310,dc2f210539245c7a03dcaa21c9305555d10ece43,abatacept,body,10.1016/j.clim.2005.03.007,FOCIS abstract supplement,2005.0,"Immunized rats were administered either 1 mg/kg abatacept or a control human IgG IP on days -1, 0, 2, 4, 6, 8 and 10 ",,True,True,0,0,0,0.0,administered
19019,20514,dc97e1de3b69da13f534f15afdcedbf48064c69d,acepromazine,body,10.1016/b978-1-4377-0798-4.00001-3,Section I Emergency Care,2012.0,"Administer acepromazine (0.02 to 0.05 mg/kg IV) or chlorpromazine (0.2 to 0.5 mg/kg IM q8h, 0.05 mg/ kg IV q4h) to control agitation",,True,True,0,0,0,0.0,Administer
19044,20541,dc97e1de3b69da13f534f15afdcedbf48064c69d,acepromazine,body,10.1016/b978-1-4377-0798-4.00001-3,Section I Emergency Care,2012.0,"Administer the anxiolytic tranquilizer acepromazine (0.02 to 0.05 mg/kg IV, IM, SQ) to decrease patient anxiety",,True,True,0,0,0,0.0,Administer
19622,21178,e33216ac315f449c13ab8445bc9eef452155d688,acetate,body,10.1016/j.cvfa.2008.10.012,Treatment of Calf Diarrhea: Antimicrobial and Ancillary Treatments,2009.0,"95, 96, 99 Acetate, propionate, and butyrate inhibit the growth of Salmonella, even in concentrations as low as 20 mmol/L 95,96 that are frequently found in ORT solutions administered to diarrheic calves",,True,False,0,0,0,0.0,administered
19624,21180,e33216ac315f449c13ab8445bc9eef452155d688,acetate,body,10.1016/j.cvfa.2008.10.012,Treatment of Calf Diarrhea: Antimicrobial and Ancillary Treatments,2009.0,"Theoretically efficacious treatments include the administration of oral rehydration therapy solutions that contain acetate and propionate, and the administration of parenteral B vitamins and fat-soluble vitamins in calves that have chronic diarrhea",,True,False,0,0,0,0.0,treatments
19651,21207,e344d21fb68d14bed65d7fbdc97164e61717a0f2,acarbose,body,10.1371/journal.pone.0029491,Predicting Biological Functions of Compounds Based on Chemical-Chemical Interactions,2011.0,"Compounds such as sulfonylureas [4] , acarbose [5] , biguanides, thiazolidinediones [5] , and sitagliptin [3] have been used as effective drugs for diabetic therapy",,False,False,0,0,0,0.0,effective
19682,21242,e35e3a46c1655f1283ea5b4999aded0d6204f738,acetate,body,10.1016/j.jep.2014.11.009,"Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: A review",2015.0,"Hexane, ethyl acetate and methanol extracts of Polygonum multiflorum (100 mg/kg) were administered i.p",,True,True,0,0,0,0.0,administered
19683,21244,e35e3a46c1655f1283ea5b4999aded0d6204f738,acetate,body,10.1016/j.jep.2014.11.009,"Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: A review",2015.0,"Both Polygonum multiflorum and Polygonum multiflorum Praeparata extracts (water-extracted, 15 g/kg/day, p.o., for 8 days) can be used to treat the hepatic lipid accumulation caused by prednisone acetate-, carbon tetrachloride-or thioacetamide-induced liver damage in mice (Liu et al., 1992) ",potential,True,True,0,0,0,1.0,treat
19697,21258,e384fc58c3ce9ec16698d34474cc97c7dc9721ab,acetaminophen,body,10.1016/s0196-0644(03)00821-7,Research forum abstracts,2003.0,"Conclusion: Patient knowledge of analgesic medications that contain acetaminophen and the maximum recommended daily dose is limited, which suggests the potential for errors in medication dosing when medications containing acetaminophen are prescribed for ED patients",,False,False,0,0,0,0.0,prescribed
19952,21535,e659993cca4cf1cc40900a6625576e8c63013602,acetaminophen,body,10.1186/s12879-017-2576-5,"The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015",2017.0,"He was prescribed ribostamycin, acetaminophen, afloqualone, rebamipide, and streptokinase; however, the fever and myalgia persisted",may,True,False,0,0,0,0.0,prescribed
20060,21653,e776f53df553e8f486d67457611ee9bce92c74c4,prednisolone,body,10.1016/b978-1-4377-1738-9.00103-1,103 Osteonecrosis,2013.0,"When mice were administered prednisolone for 27 days, increased metaphyseal apoptotic activity of both osteoblasts and osteoclasts were noted",,False,False,0,0,0,0.0,administer
20061,21654,e776f53df553e8f486d67457611ee9bce92c74c4,acetate,body,10.1016/b978-1-4377-1738-9.00103-1,103 Osteonecrosis,2013.0,"Nonsurgical ACTH is administered along with depot methylprednisolone acetate (DepoMedrol), osteonecrosis is reduced",,False,False,0,0,0,0.0,administer
20062,21655,e776f53df553e8f486d67457611ee9bce92c74c4,methylprednisolone,body,10.1016/b978-1-4377-1738-9.00103-1,103 Osteonecrosis,2013.0,"Nonsurgical ACTH is administered along with depot methylprednisolone acetate (DepoMedrol), osteonecrosis is reduced",,False,False,0,0,0,0.0,administer
20252,21855,e9f49e2685338d697a7405e7ad6424385fd129b6,acetaminophen,body,10.1016/j.jep.2018.03.038,Therapeutic potentials of Houttuynia cordata Thunb. against inflammation and oxidative stress: A review,2018.0,"With the treatment of HC aqueous extract (2 g/l) showed suppressing CYP2E1 activity and reversing of antioxidant enzymes like hepatic GSH, catalase, SOD, GPx activity along with decrease ROS, lipid peroxidation, oxidized glutathione (GSSG) in acetaminophen-induced BALB/cA mice (Chen et al., 2014b) ",,True,False,0,0,0,1.0,treatment
20317,21921,ea763d76c18c169dbea960bd078460b0e60445fb,testosterone,body,10.1016/0007-1935(92)90044-2,Equine arteritis virus: An overview,1992.0,(1991) have recently demonstrated by administering testosterone to castrated stallions that the persistence of EAV in chronically infected stallions is mediated either directly or indirectly by testosterone and consequently dependent on the presence of the testes ,may,True,False,0,0,0,0.0,administering
20342,21948,ea8cc2ba1bdda814040cf9a1a68813f18cda0690,testosterone,body,10.1016/s0045-9380(79)80017-1,Chronic diarrhea,1979.0,"In a few patients anemia may respond to folic acid, vitamin B12 or testosterone, but in most it is refractory and must be managed by transfusion.",,True,False,0,0,0,0.0,managed
20467,22078,ec5c5cf696f081cdd0cbbe5ed8082a162d41954d,acetaminophen,body,10.1016/b978-0-323-01199-0.50069-4,Chapter 64 Disorders of the Pharynx,2005.0,"Pharyngitis usually is viral in origin and may be treated symptomatically with analgesics, such as acetaminophen or ibuprofen, to relieve pain of pharyngitis and promote oral hydration",,False,False,0,0,0,0.0,treated
20538,22154,ed99e6a929c6b77dbeaeeb4220c1a1d17a15d73a,acetaminophen,body,10.1016/s1081-1206(10)60603-5,"Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial",2008.0,"Participants with symptoms were also asked about the number of days missed from work and any medications used to treat symptoms, (eg, aspirin, acetaminophen, vitamins, and cold formulas)",,True,False,0,0,0,0.0,treat
20826,22466,f0dfd00ebde7ca0adb30e41aee2b4abed598603b,acetate,body,10.1016/j.cvsm.2011.08.007,"Canine Reproductive, Respiratory, and Ocular Diseases due to Canine Herpesvirus",2011.0,Ledbetter and colleagues 15 also administered topical ocular prednisolone acetate or a placebo to mature dogs experimentally inoculated with CHV via the ocular route and previously tested for reactivatable latency by systemic administration of an immunosuppressive dose of corticosteroids,,True,False,0,0,0,0.0,administered
20967,22613,f292235c8719f67efdebdacd495a2131a70b05b8,acetaminophen,body,,,,"52 At the moment, the effects of other environmental exposures on the development of asthma remain controversial with respect to planning interventions, including the use of acetaminophen to treat fevers of young children, early childhood vaccines, and exposure to parasitic infections",may,True,False,0,0,0,0.0,treat
21431,23112,f7748ce96d52eeafe6b08a42b2f9f1774b373f78,abatacept,body,10.1083/jcb.201706157,Beyond self-eating: The control of nonautophagic functions and signaling pathways by autophagy-related proteins,2018.0,"The CTLA4-Ig fusion molecule abatacept, which is used to treat RA, also inhibits ATG-mediated antigen presentation by dendritic cells, suggesting that dampening autophagy is part of the mechanism of action of this drug (Alissafi et al., 2017) ",potential,True,True,0,0,0,0.0,treat
21742,23446,fb63b69994ff9a8008a340abf1d2451b2de93e85,acetate,body,10.1016/j.jfms.2008.02.006,Pathogenesis of feline enteric coronavirus infection,2008.0,Methylprednisolone acetate (5 mg/kg) was administered twice intramuscularly at a 3-week interval to 10 randomly selected cats from the project; eight cohort cats were given saline (Table 1 ),,True,True,0,0,0,0.0,administer
21748,23453,fb9d6eae91539cd03cf4c1f0b1bfaa6b5dab480c,acetylcholine,body,10.1016/s0065-2776(08)60634-3,The Regulation of Pulmonary Immunity,1995.0,These animals also demonstrate increased bronchial reactivity to histamine or acetylcholine administered iv,,False,False,0,0,0,0.0,administer
21883,23596,fcd0b20d3b55d4c5029f98c3612ff577394ebf3d,acetate,body,10.1186/s12917-017-1143-z,Highly suspected cases of salmonellosis in two cats fed with a commercial raw meat-based diet: health risks to animals and zoonotic implications,2017.0,"The cat was hospitalized for 6 days and treated intravenously with: fluid therapy (Ringer's acetate), Metronidazole antibiotic (10 mg/kg bid -Deflamon 500 mg/100 mL), Enrofloxacin antibiotic (5 mg/kg sid -Baytril 50 mg/ml), S-Adenosylmethionine (20 mg/kg sid -Samyr 400 mg/ 5 ml)",,True,False,0,0,0,0.0,treated
21884,23597,fcd0b20d3b55d4c5029f98c3612ff577394ebf3d,acetate,body,10.1186/s12917-017-1143-z,Highly suspected cases of salmonellosis in two cats fed with a commercial raw meat-based diet: health risks to animals and zoonotic implications,2017.0,"The cat was hospitalized for 6 days and treated intravenously with: fluid therapy (Ringer's acetate), Metronidazole antibiotic (10 mg/kg bid -Deflamon 500 mg/100 mL), Enrofloxacin antibiotic (5 mg/kg sid -Baytril 50 mg/ml), S-Adenosylmethionine (20 mg/kg sid -Samyr 400 mg/ 5 ml)",,True,False,0,0,0,0.0,treated
21915,23630,fd475ddc3ccb71cccd12f9d04991df38decd3c36,acetate,body,10.1016/b0-72-160423-4/50006-8,Chapter 3 Infectious Uveitis,2006.0,"60, 61 When present, anterior uveitis should be treated with a topical GC, such as 1 per cent prednisolone acetate, and atropine",,True,False,0,0,0,0.0,treated
22023,23754,feb5fe50c9b52f37dec75d7d3c4c7601195f6106,acetate,body,10.1016/b978-044452771-4/50009-2,8 Digestive System,2007.0,"Like the spontaneous condition, these changes were characterized by thickening of the mucosa by hyperplasia of the foveolar and neck regions, and downward proliferation of glandular elements into gastric glands.^^^ Similar glandular hyperplasia in the mouse stomach alongside neuroendocrine alterations has been associated with histamine H2 blockade with the agent ioxtidine.^^^ Adenomatous polyps have also been reported in the pyloric antrum of C57B1/10J mice treated for 52 weeks with the synthetic progestin, cyproterone acetate.^^^ These were single, pedunculated and well-differentiated lesions showing little evidence of dysplasia",,True,True,0,0,0,1.0,treated
22140,23877,ff1cc08ebe7f5a104152662fa87ff683524165c7,acetate,body,10.1016/b978-0-443-07151-5.50005-6,Chapter 3 SPECIFIC PROBLEM AREAS,2007.0,"Other cancer drugs: â–  Various hormones are used to control some tumours, especially in the case of breast (ethinyloestradiol, medroxyprogesterone, norethisterone or megestrol) and prostate cancers (diethylstilboestrol, fosfestrol) â–  Hormone antagonists are used in some tumours, such as breast (tamoxifen, toremifene, aminoglutethimide, anastrozole, letrozole, exemestane, trilostane, goserelin) and prostate cancers (buserelin, goserelin, leuprorelin, triptorelin, cyproterone acetate, flutamide, bicalutamide) â–  Antibodies made specifically to attach to cancer cells and linked to a toxin or radioactive substance can kill the cell â–  Gene therapy is being developed to replace damaged tumour suppressor genes, or otherwise influence cell activity",,True,False,0,0,0,0.0,therapy
22159,23896,ff1cc08ebe7f5a104152662fa87ff683524165c7,acetaminophen,body,10.1016/b978-0-443-07151-5.50005-6,Chapter 3 SPECIFIC PROBLEM AREAS,2007.0,"Adjuvant drugs to enhance analgesic efficacy, treat concurrent symptoms that exacerbate pain, and provide independent analgesic activity for specific types of pain may be used at any step: â–  Step 1, for mild to moderate pain, involves the use of paracetamol/ acetaminophen, aspirin, or another NSAID â–  Step 2, when pain persists or increases, advises that an opioid such as codeine or hydrocodone should be added (not substituted) to the analgesic regimen",may,True,False,1,1,0,0.0,treat
22238,23976,ff292a9fce88c9c34f9ffe636729dc31c20cf300,acetate,title,10.1292/jvms.16-0297,Effect of acetate Ringer(â€™)s solution with or without 5% dextrose administered intravenously to diarrheic calves,2017.0,Effect of acetate Ringer ' s solution with or without 5% dextrose administered intravenously to diarrheic calves,,True,True,1,1,0,0.0,administered
22239,23977,ff292a9fce88c9c34f9ffe636729dc31c20cf300,acetate,title,10.1292/jvms.16-0297,Effect of acetate Ringer(â€™)s solution with or without 5% dextrose administered intravenously to diarrheic calves,2017.0,Effect of acetate Ringer ' s solution with or without 5% dextrose administered intravenously to diarrheic calves,,True,True,1,1,0,0.0,administered
22242,23980,ff292a9fce88c9c34f9ffe636729dc31c20cf300,acetate,title,10.1292/jvms.16-0297,Effect of acetate Ringer(â€™)s solution with or without 5% dextrose administered intravenously to diarrheic calves,2017.0,Effect of acetate Ringer ' s solution with or without 5% dextrose administered intravenously to diarrheic calves,,True,True,1,1,0,0.0,administered
22243,23981,ff292a9fce88c9c34f9ffe636729dc31c20cf300,acetate,title,10.1292/jvms.16-0297,Effect of acetate Ringer(â€™)s solution with or without 5% dextrose administered intravenously to diarrheic calves,2017.0,Effect of acetate Ringer ' s solution with or without 5% dextrose administered intravenously to diarrheic calves,,True,True,1,1,0,0.0,administered
22324,24065,ffed51538e59e779838ead9f15f10d906791b4bd,acetate,body,10.1016/s0031-3955(05)70198-x,MEDICAL MANAGEMENT OF HIV DISEASE IN CHILDREN,2000.0,"Megestrol acetate is an orally administered, synthetic, progestational agent initially used to increase the appetite of patients with cancer",,True,True,0,0,0,0.0,administer
